Human Induced Pluripotent Stem Cell- and mRNA-based Gene Therapy Strategies for Treatment of Arginase Deficiency by Truong, Brian
UCLA
UCLA Electronic Theses and Dissertations
Title
Human Induced Pluripotent Stem Cell- and mRNA-based Gene Therapy Strategies for 
Treatment of Arginase Deficiency
Permalink
https://escholarship.org/uc/item/9gd7r3d8
Author
Truong, Brian
Publication Date
2019
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
	UNIVERSITY OF CALIFORNIA 
Los Angeles 
 
 
 
 
Human Induced Pluripotent Stem Cell- and mRNA-based Gene Therapy Strategies for 
Treatment of Arginase Deficiency 
 
 
 
 
A dissertation submitted in partial satisfaction of the requirements for the degree 
Doctor of Philosophy In Molecular and Medical Pharmacology 
 
by 
 
Brian Truong 
 
2019 
 
 
 
 
 
 
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by 
Brian Truong 
2019
ii 
ABSTRACT OF THE DISSERTATION 
 
Human Induced Pluripotent Stem Cell- and mRNA-based Gene Therapy Strategies for 
Treatment of Arginase Deficiency 
 
by 
 
Brian Truong 
Doctor of Philosophy in Molecular and Medical Pharmacology 
University of California, Los Angeles, 2019 
Professor Gerald S. Lipshutz, Chair 
 
Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and 
typically lead to hyperammonemia. Arginase deficiency is caused by biallelic mutations in 
ARG1, the final step of the urea cycle, and results biochemically in hyperargininemia and the 
presence of circulating guanidino compounds while clinically is notable for developmental 
delays, spastic diplegia, psychomotor function loss, and uncommonly, death. There is currently 
no completely effective medical treatment available. Current medical treatments for urea cycle 
disorders are only marginally effective, and for proximal disorders, liver transplantation is 
effective but limited by graft availability. 
 
Restoring Ureagenesis in Hepatocytes by CRISPR/Cas9-mediated Genomic Addition to 
Arginase-Deficient Induced Pluripotent Stem Cells 
Advances in human induced pluripotent stem cell research has allowed for the genetic 
modification of stem cells for potential cellular replacement therapies. In this study, we 
demonstrate a universally-applicable CRISPR/Cas9-based strategy utilizing exon 1 of the 
iii 
hypoxanthine-guanine phosphoribosyltransferase locus to genetically modify and restore 
arginase activity, and thus ureagenesis, in genetically distinct patient-specific human induced 
pluripotent stem cells and hepatocyte-like derivatives. Successful strategies restoring gene 
function in patient-specific human induced pluripotent stem cells may advance applications of 
genetically modified cell therapy to treat urea cycle and other inborn errors of metabolism. 
 
Lipid Nanoparticle Targeted mRNA Therapy as a Treatment for the Inherited Metabolic Liver 
Disorder Arginase Deficiency 
While preclinical strategies have been demonstrated, disadvantages with viral-based 
episomal-expressing gene therapy vectors include the risk of insertional mutagenesis and 
limited efficacy due to hepatocellular division and patient-specific genetically modified cell 
therapies suffer from lengthy preparation time where patients with urea cycle disorders (UCDs) 
are at continued risk for progressive intellectual decline. Recent advances in mRNA codon 
optimization, synthesis, and encapsulation within biodegradable liver-targeted lipid 
nanoparticles (LNPs) have potentially enabled a new generation of rapidly applicable and safer, 
albeit temporary, treatments to restore liver metabolic function in patients with UCDs including 
arginase deficiency. In this study, we applied such technologies to successfully treat an 
arginase deficient murine model. Mice were administered LNP encapsulating human codon-
optimized ARG1 mRNA every 3 days and demonstrated 100% survival with no evidence of 
hepatotoxicity. Plasma ammonia, arginine, and glutamine demonstrated good control and near-
normal ureagenesis was measured. These results suggest that hARG1 mRNA delivery by liver-
targeted nanoparticles may be a viable gene-based therapeutic for the treatment of arginase 
deficiency. 
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INTRODUCTION  
 
Urea cycle disorders (UCDs) are rare enzymopathies with an incidence of 1:35,000 
births resulting in approximately 113 new cases per year in the United States [1]. UCDs result 
from a deficiency in one of six hepatic enzymes or two mitochondrial transporters that regulate 
nitrogen metabolism and urea production and are typically classified as inborn errors of 
metabolism [1-4]. They are a significant cause of inherited hyperammonemia and afflicted 
infants and newborns are at substantial risk of recurrent brain injury and death. Severity of the 
UCD is influenced by the enzyme’s position in the urea cycle as deficiencies in more proximal 
enzymes such as carbamoyl phosphate synthase I (CPS1), ornithine transcarbamylase (OTC), 
argininosuccinic acid synthetase (ASS1), and argininosuccinic acid lyase (ASL) result in 
ammonia and metabolite accumulation within the first few days of life while a deficiency in 
arginase I (ARG1), the last enzyme, uncommonly causes hyperammonemia in patients [5].  
Excessive plasma ammonia is neurotoxic, resulting in central nervous system injury including 
intellectual disabilities, seizures, and loss of psychomotor function [1-4, 6]; they also live with 
continued nitrogen vulnerability. However, the exact mechanism by which ammonia causes 
brain damage continues to be under investigation; current theories implicate that increased 
glutamine accumulation, by condensation of excess ammonia and glutamate by glutamine 
synthetase, causes osmotic stress to astrocytes and cerebral edema [5, 7]. Additional factors 
also likely play a role as clinical outcomes of proximial UCDs with more severe 
hyperammonemia phenotypes do not seem to differ from the more distal UCDs [8]. Treatment 
strategies for specific urea cycle disorders vary, but generally involve dietary protein restriction 
and emergency treatments for acute hyperammonemic episodes by dialysis or pharmacologic 
intervention using nitrogen scavengers such as sodium phenylacetate and sodium benzoate [5]. 
Liver transplantation for treatment of UCDs, though curative, has generally only been 
recommended for patients suffering from neonatal onset of OTC and CPS1 deficiency or 
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patients where conventional treatment strategies fall short [5, 9]. However, liver transplants are 
severely limited in availability and patients can suffer from short- and long-term consequences 
of immunosuppression [10].   
Arginase deficiency (MIM#207800) is an uncommon autosomal recessive disorder 
(estimated incidence of 1:950,000 in the United States [1]) that results from loss of ARG1 (EC 
3.5.3.1). ARG1 is the final enzyme of the urea cycle completing the major metabolic pathway for 
the disposal of excess nitrogen in terrestrial mammals. Along with red blood cells, the cytosolic 
enzyme is most prevalent in hepatocytes hydrolyzing arginine into ornithine, which then re-
enters the cycle, while nitrogen, in the form of urea, is excreted as waste in the urine [11]. The 
typical presentation of arginase deficiency is different than that of the other UCDs with onset of 
symptoms typically in late infancy. Outcomes include microcephaly, seizures, loss of 
ambulation, clonus, spastic diplegia, intellectual disability (from mild to severe), growth 
deficiency and failure to thrive [3, 12]; the exact cause of these neurologic manifestations and 
the progressive intellectual decline is not known but is hypothesized to be related to 
hyperargininemia and the accumulation of guanidino compounds (as putative neurotoxins) 
found in the plasma, urine and cerebrospinal fluid of these patients [13-18]. Unlike the other 
enzyme deficiencies of the urea cycle, hyperammonemia is uncommon [19] and thus patients 
typically avoid the severe nitrogen vulnerability and catastrophic crises that occur in the other 
UCDs. However, the neurological decline is progressive and unrelenting, and the mainstay of 
current day therapy, which includes provision of a very strict protein-restricted diet, amino acid 
supplementation, and the administration of nitrogen scavengers [3, 12], only partially alleviates 
the disorder as there exists no medical therapy that is completely efficacious. While liver 
transplantation has not been commonly employed for patients with this disorder, long-term 
follow-up of two patients who underwent liver transplantation showed normalization of plasma 
arginine and guanidino compounds with lack of progressive neurological decline [20, 21], further 
supporting methods of normalization of plasma arginine levels as tenets of therapy. 
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With the advent of transgenic technology, the development of gene therapies for 
treatment of inherited monogenic disorders have significantly advanced over the last two and a 
half decades. Broadly applicable, gene therapy strategies have been investigated for a wide 
range of disorders including hemoglobinopathies such as beta-thalassemia and sickle cell 
anemia, primary immune deficiencies such as X-linked SCID and adenosine deaminase 
deficiency, bleeding disorders such as hemophilia A and B, and liver metabolic disorders such 
as UCDs [22, 23]. Viral vectors such as the adenovirus, γ-retrovirus, lentivirus, and adeno-
associated virus (AAV) have long been the vehicles of choice for the delivery of genetic cargo to 
restore enzymatic function to cells [24]. However, advantages and disadvantage of each viral 
vector must be evaluated depending on disease context. Our group, like other groups 
investigating gene therapy strategies for treatment of liver metabolic disorders, have veered 
away from using the highly immunogenic adenovirus despite its high hepatotropism and large 
genetic cargo capacity (~7.5 kb) in place of AAV with its minimal immunogenic response despite 
its limited genetic cargo capacity (~4 kb) [24]. After developing a mouse model of arginase 
deficiency that recapitulates several pathobiological aspects of the human condition such as 
hyperargininemia, hyperammonemia, plasma amino acid profile abnormalities, and mental 
impairment [25], our group has been successful in demonstrating pre-clinical application of viral-
based gene therapy approaches for treating the disorder [26-28]. However, our studies have 
revealed significant challenges associated with using episomal-based viral vectors for direct 
systemic in vivo genetic delivery mainly highlighted by loss of episomal vector copy number in 
the rapidly dividing hepatic neonatal murine liver [28]. Therefore, our group has focused on 
developing novel gene therapy approaches for treatment of arginase deficiency that avoid the 
complications arising from use of viral vectors.  
 Liver transplantation has evidence to be the only long-term and curative treatment for 
UCDs that eliminate the need for daily restrictive diets and absolves the fear of stressors 
potentially initiating a life threatening hyperammonemic crises [5]. Though uncommonly 
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employed, liver transplantation has been demonstrated to be curative in two patients of arginase 
deficiency [20, 21]. However, due to the extremely limited availability, liver transplantations are 
often restricted to severe cases such as neonatal onset of CPS1 and OTC deficiency. 
Therefore, a potential alternative to liver transplantation is hepatocyte transplantation. 
Hepatocytes can be isolated from donor livers unsuitable for liver transplantation or from liver 
segments I and IV available after split liver transplantation [29]. For treatment of UCDs, the 
majority of the native liver remains functional while transplanted hepatocytes would serve as a 
living cellular source of full urea cycle function capable of engrafting, expanding and growing 
with the patient. Hepatocyte transplantation has some theoretical advantages compared to liver 
transplantation including being less invasive, being less costly, allowing for multiple transplants, 
the availability of cryopreserved cells, and multiple patients can be treated with a single donor 
organ [29]. However, in addition to the still quite limited availability of donors, long-term efficacy 
of these grafts is still being investigated and optimized as insufficient engraftment and graft 
rejection currently limits their widespread clinical application [29].  
Therefore, a potential alternative source for cells could be patient-specific human 
induced pluripotent stem cell (hiPSC)-derived hepatocyte-like cells (HLCs). Since the 
demonstration that human fibroblasts could be reprogrammed to a pluripotent stem cell state by 
overexpression of four defined transcription factors (OCT4, SOX2, KLF4, and cMyc), the field of 
disease modeling and especially, personalized regenerative medicine was revolutionized [30, 
31]. Furthermore, researchers invested significant time and resources to elucidate the molecular 
pathways and examine applicability and optimization of available differentiation protocols to 
drive hiPSCs down specific disease-relevant cell lineages such as retinal pigment epithelium for 
age-related macular degeneration [32], neurons for Parkinson’s disease [33], cardiomyocytes 
for heart disease [34], and especially, hepatocytes for liver metabolic disorders and liver disease 
[35-39]. These hiPSC-derived HLCs demonstrate phenotypic similarities to endogenously 
derived hepatocytes and can be successfully transplanted and contribute to liver function in 
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various animal models [40]. Additionally, as these hiPSC-derived HLCs would be autologously 
transplanted back into the same patient, this would theoretically preclude the need for life-long 
immunosuppression. Thus, with the advancements made to progress the ability to differentiate 
an unlimited supply of functional hiPSC-derived HLCs, comes the question of whether these 
cells can be used to treat inherited liver metabolic disorders such as UCDs. However, as these 
hiPSCs would continue to possess the inherited genetic mutation, methods to restore functional 
enzyme expression need to be explored.  
 Conventional randomly integrating viral and non-viral approaches to genomically modify 
hiPSCs for gene correction are either inefficient or can result in insertional mutagenesis and 
malignant transformation [41]. The clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9 system is adapted from a prokaryotic immune system response where foreign 
genetic material is recognized by CRISPR spacers and is removed from the bacterial genome 
[42]. The engineered CRISPR/Cas9 system contains: 1) a guide RNA including a scaffold 
sequence required for Cas9 endonuclease-binding and a spacer sequence that binds to the 
desired genomic target and 2) the Cas9 endonuclease that facilitates nuclease activity [43-45]. 
Using this CRISPR/Cas9 system, genomic modification, by site-specific homologous 
recombination at well-defined loci, can efficiently introduce transgenic elements to safe harbor 
chromosomal loci in hiPSCs and thereby minimize safety concerns. Furthermore, recent studies 
have demonstrated the feasibility of CRISPR/Cas9-mediated genomic modification of hiPSCs 
and subsequent differentiation to disease-relevant cell types such as muscle cells, neural 
lineages, and HLCs [46-48].  
Though promising, generating a large population of patient-specific hiPSC-derived HLCs 
that have been genomically modified for restored enzyme function can take up to several 
months beginning from a patient skin punch biopsy. However, if recognized at the time of typical 
symptom presentation, UCD patients may undergo irreversible progressive intellectual decline 
during this period even with current mainstay treatment strategies. Therefore, RNA-based 
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therapeutics may serve as a readily available source of enzymatic function to bridge the gap 
until the cellular therapy is available. Though in vivo delivery of mRNA to sites of missing 
enzyme function is not a new concept, recent advances have been made to increase efficiency 
and efficacy of this treatment modality to become clinically relevant [49]. Delivery of unmodified 
mRNA elicits a cellular innate immune system response as Toll-like receptors can recognize 
single stranded mRNA in the endosome [49]. Therefore, many investigators have turned to 
developing chemically modified mRNA. These chemically modified mRNAs often contain 
modified 5’ caps, modified nucleosides such as pseudouridine and 5-methylcytidine, sequence 
codon optimization, and optimized 3’ untranslated regions that altogether help avoid innate 
immunity, aid in mRNA stability, and increase translatability [49]. Even still, it is required to 
encapsulate the mRNA in order to protect and efficiently deliver the mRNA to target cells or 
sites in vivo.    
Lipid nanoparticles (LNPs) are lipid-based particles that have been formulated to 
encapsulate nucleic acids for research and drug delivery purposes. Therapeutically, LNPs have 
been demonstrated to encapsulate small interfering RNA, microRNAs, messenger RNA, and 
DNA. LNPs generally consist of four components: an ionizable cationic lipid that facilitates 
encapsulation, cellular uptake, and endosomal escape of negatively charged nucleic acids, a 
helper lipid such as phosphatidylcholine and cholesterol that both provide LNP structural 
framework, and a coat lipid such as lipid-anchored polyethylene glycol (PEG) that increases 
blood circulation time and confers immune response evasion properties [50]. Additionally, with 
the common use of ionizable cationic lipids, resulting liposomes become neutrally charged in 
the blood circulation and bind to serum proteins such as apolipoprotein E facilitating uptake into 
target cells with high density of its LDL receptor such as hepatocytes [50]. Therefore, by 
encapsulating the chemically modified mRNAs with these optimized LNPs, we now have the 
tools to develop efficacious therapies to deliver enzymatic function to UCD patients. 
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CHAPTER 1: Restoring Ureagenesis in Hepatocytes by CRISPR/Cas9-mediated Genomic 
Addition to Arginase-Deficient Induced Pluripotent Stem Cells 
 
Introduction 
The urea cycle is the major pathway for detoxification of ammonia and the only pathway 
for regulating and disposing of excess nitrogen in mammals. Inherited defects in each of its 
eight steps including six hepatic enzymes and two mitochondrial transporters are known [1]. 
Though generally considered uncommon, UCDs are a significant cause of inherited 
hyperammonemia and represent a substantial cause of brain damage and death in afflicted 
infants and newborns with many cases remaining undiagnosed. For arginase deficiency, 
patients have a mutation in arginase 1 (ARG1), which regulates the final step of nitrogen 
removal in the urea cycle converting arginine into urea leading to hyperargininemia. Loss of 
ARG1 activity results in an inability to remove nitrogen from arginine, but rarely causes 
symptoms of hyperammonemia. Instead, the cause of the pathogenesis of neurological 
deterioration in arginase deficiency is not known and is thought to be due to unique biochemical 
abnormalities such as elevated guanidino compounds, nitric oxide, or glutamine [3, 51-53].  
As there is no completely effective treatment for UCDs, the mainstay of therapy is 
dietary protein restriction, with emergency treatments for hyperammonemia consisting of 
dialysis, hemofiltration and intravenous administration of nitrogen scavenging drugs [4]. Chronic 
therapy is minimally effective in reducing plasma ammonia while control of hyperargininemia 
may delay the onset of symptoms [11, 51] but may not ultimately prevent the progressive and 
relentless nature of neurocognitive decline. Liver transplantation is the extreme alternative to 
conventional therapies to prevent progression of neurological injury in UCD patients. However, 
the demand for liver donors far exceeds the supply, and other avenues, such as genetic 
modification and cell replacement therapy, need to be explored to treat these disorders. 
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Since the demonstration that human induced pluripotent stem cells (hiPSCs) could be 
reprogrammed from fibroblasts with four transcription factors (OCT4, SOX2, KLF4, and cMyc), 
hiPSCs have emerged as a potential avenue for patient-specific disease modeling and 
development of therapy [30, 31, 54-56]. Whereas the difficulty in obtaining primary cell cultures 
previously hindered progress of disease research, the ability of patient-specific hiPSCs to 
differentiate into genetically similar somatic cell types of various lineages, such as hepatocytes, 
allows for the generation of a substantial quantity of patient-specific cells [37, 38]. These hiPSC-
derived hepatocytes express liver-specific markers such as albumin (ALB), alpha-fetoprotein 
(AFP), and cytokeratin 18 (CK18) as well as functionality markers such a1-antitrypsin (AAT) and 
CYP3A4, demonstrating their phenotypic similarity to endogenously derived hepatocytes [38]. 
Reprogramming patient-specific hiPSCs and establishing isogenic and functional derivatives 
afford the advantage of avoiding the ethical controversy of oocyte-derived embryonic stem cell 
use and potentially addressing the immunogenicity issues for cell replacement therapies [57]. 
In this study, we sought to correct the enzyme deficiency, using a universal approach, in 
multiple arginase-deficient hiPSC lines derived from hyperargininemic patients by using genome 
editing technology. We delivered CRISPR/Cas9 nickases via nucleofection for gene addition of 
a full-length codon-optimized human arginase 1 cDNA (ArgO) expression cassette (LEAPR) into 
Exon 1 of the endogenous hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus in 
hiPSCs [58]. After targeted insertion and puromycin selection (enabled by the LEAPR-derived 
puromycin N-acetyl-transferase [PAC]), and with confirmation of the presence of the LEAPR 
cassette in the patient-specific hiPSCs, we demonstrated the restoration of arginase activity in 
both hiPSCs and differentiated hepatocyte-like cells (HLCs). Additional efforts were also 
performed to optimize the LEAPR expression cassette and HLC differentiation protocol. An 
AFP-Reporter/Selection Construct was also developed and investigated to determine if HLCs 
could be isolated by AFP expression. Lastly, corrected HLCs were transplanted into an 
immunosuppressed mouse model of hyperarginininemia. Results from this genetic targeting 
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approach potentially offer a widely applicable method to genetically introduce arginase 
expression in hiPSCs derived from hyperargininemic patients and, on a broader scale, to other 
single-enzyme inborn errors of metabolism. 
 
Materials and Methods 
In vitro derivation and culture of primary human dermal cells 
The control human dermal fibroblast cell line (xcHUF1), obtained from UCLA Good 
Manufacturing Practice (GMP) facility [59], and two disease fibroblast lines (AD2 and AD3) used 
in this study were obtained from adult skin punch biopsy (after IRB approval and informed 
consent) and were cultured in methods previously published [54, 60]. One adult disease 
fibroblast line (GM00954, renamed AD1) was obtained from Coriell Institute for Medical 
Research (Camden, NJ). All procedures were approved by the Institutional Review Board (IRB 
#13-001469-AM-00002) and the Embryonic Stem Cell Research Oversight (ESCRO) (ESCRO 
#2010-010-04A) Committee of the University of California, Los Angeles and informed consent 
was documented from both patients. 
All fibroblast lines were cultured in media consisting of Dulbecco’s modified Eagle 
medium nutrient mixture/F-12 (DMEM/F-12) (Invitrogen, Grand Island, NY), 10% fetal bovine 
serum (FBS) (Invitrogen), 1x Glutamax (Invitrogen), 1x minimum essential medium nonessential 
amino acid (Invitrogen) and 1x Primocin (InvivoGen, San Diego, CA). Cells were maintained in a 
37°C 5% CO2 incubator. Media was changed every 1-2 days and cells were passaged with 
0.05% trypsin-ethylenediamine tetraacetic acid (EDTA) (Gemini Bio-Products, West 
Sacramento, CA). 
 
In vitro derivation and culture of human stem cell lines 
The control hiPSC line xc-HUF1 and the three disease hiPSC lines (AD1, AD2, AD3) 
were developed by reprogramming from corresponding parental fibroblast lines via a lentiviral 
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transduction of a stem cell cassette (STEMCCA) containing the reprogramming factors Oct4, 
Sox2, Klf4, and c-Myc [61]. 
Fibroblasts were seeded at a confluency of 10,000 cells/cm2 prior to transfection. After 
viral transduction, cells were maintained in a 37°C 5% CO2 incubator for 3 days in a defined 
media consisting of DMEM/F-12 (Invitrogen) supplemented with 20% Knockout Serum 
Replacement (Invitrogen), 1x Glutamax (Invitrogen), 1x Minimal Essential Media Non-Essential 
Amino Acids Solution (Invitrogen), 1x Primocin (InvivoGen), 1x b-mercaptoethanol (Millipore, 
Billerica, MA), and 10 mg/mL basic fibroblast growth factor (bFGF) (Biopioneer, San Diego, CA). 
After 3 days, the cells were passaged with 0.05% trypsin EDTA (Gemini Bio-Products) onto a 
layer of mouse embryonic fibroblasts (MEFs) (GlobalStem, Rockville, MD) and maintained in 
culture up to 30 days until putative hiPSC colonies began to form. 
All cells were transitioned to and subsequently maintained in feeder-free culture 
conditions consisting of reduced growth factor Matrigel (BD Biosciences, San Jose, CA) and a 
50:50 mix of mTeSR1 media (StemCell Technologies, Vancouver, BC, Canada) and Nutristem 
(Stemgent, San Diego, CA) supplemented with 1x Primocin (InvivoGen) and 10 mg/mL bFGF. 
Cells were mechanically passaged every 4 to 5 days, depending on confluency and colony size. 
To passage the cells, pulled glass pipettes were used to cross-hatch the colonies and to lift the 
pieces gently for transfer onto new Matrigel-coated plates. 
 
DNA delivery by nucleofection 
Cells were prepared for nucleofection by aspirating the media from each well and 
replacing with 2 ml of mTeSR/Nutristem media supplemented with 10 mM ROCK inhibitor 
(BioPioneer, San Diego, CA). After 1 hour, the media was again aspirated and replaced with 1 
mL Stempro Accutase (Life Technologies) and incubated at 37ºC for 4-6 minutes in 1-2 mL of 
mTeSR1/Nutristem media supplemented with 10 µM ROCK inhibitor in each well to neutralize 
the Accutase. Cells were then washed and gently scraped into suspension. The cell suspension 
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was transferred to a sterile 15 mL conical tube and centrifuged for 5 minutes at 80 x g. The 
supernatant was aspirated and the cells were resuspended in an appropriate volume of 
mTeSR1/Nutristem media with ROCK inhibitor. 10 ml of the resuspended sample was removed 
and counted by hemocytometer. Samples planned for nucleofection were prepared as 800,000-
1 million cells each. Aliquots were centrifuged for 5 minutes at 80 x g. Supernatant were 
aspirated and the cells were resuspended in 100 ml of nucleofection solution (Lonza) and 
placed into nucleofection cuvettes. (Care was taken to carefully resuspend cells to maximize the 
amount of single cells in suspension and to minimize cell death due to excessive mechanical 
stress). 1-2 µg of each DNA vector was added and mixed into the nucleofection solution. 
Controls, 1-2 µg of pMAX-GFP, which is included in the kit, were added to one aliquot of each 
cell solution. The samples were then securely placed into an Amaxa Nucleofector II (Lonza) and 
nucleofected using the B-016 program to facilitate cellular DNA vector uptake. The cells were 
then pipetted into either previously prepared Matrigel-coated plates or directly onto previously 
prepared plates of MEFs. 72 hours after plating, mTeSR1/Nutristem media was supplemented 
with 1 µg/ml of puromycin for an additional 72 hours. Following puromycin selection, cells were 
cultured in mTeSR1/Nutristem media without puromycin. Colonies were expanded until large 
enough to isolate by mechanical passaging. 
 
Hepatocyte differentiation of induced pluripotent stem cells 
To begin hepatocyte differentiation, hiPSCs were passaged at 90% confluency. The next 
day, the differentiation protocol began as previously published by Song et. al. [38]. Briefly, 
hiPSCs were incubated for 24 hours with Roswell Park Memorial Institute (RPMI) 1640 medium 
(Life Technologies, Carlsbad, CA), and supplemented with 0.5 mg/ml bovine serum albumin 
(Sigma-Aldrich, St. Louis, MO), 100 ng/mL Recombinant Human Activin A (Peprotech, Rocky 
Hill, NJ), and 1x Primocin (Invivogen). On days 2 and 3, 0.1% and 1% insulin-transferrin-
selenium (Life Technologies) were added to the previous supplemented RPMI 1640 medium, 
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respectively. On day 4, hiPSCs were cultured with Hepatocyte Culture Medium (HCM) 
(consisting of HBM Basal Medium and HCM SingleQuot Kit) (Lonza, Walkersville, MD) 
supplemented with 30 ng/mL Recombinant Human Fibroblast Growth Factor-4 (FGF-4) 
(Peprotech), 20 ng/mL Bone Morphogenetic Protein-2 (BMP-2) (Peprotech), and 1x Primocin 
(Invivogen) for 4 days. The differentiated cells were then cultured in HCM containing 20 ng/ml 
Recombinant Human Hepatocyte Growth Factor (HGF), 20 ng/mL Recombinant Human 
Keratinocyte Growth Factor (KGF), and 1x Primocin (Invivogen) for 6 days, and in HCM 
supplemented with 10 ng/ml Recombinant Human Oncostatin M (OSM) (R&D Systems, 
Minneapolis, MN), 0.1 mM dexamethasone (Sigma), and 1x Primocin (Invivogen) for the 
following 5 days. For the last 3 days of the hepatic differentiation, the cells were cultured in 
DMEM/F:12 (Life Technologies) supplemented with 1x N2, 1x B27, 1x GlutaMAX (Life 
Technologies), 1x NEAA (Life Technologies), 0.1 mM β-mercaptoethanol (Life Technologies), 
and 1x Primocin (Invivogen). All media and supplements were filtered prior to use with a 0.22 
micron filter and media was changed daily. 
Alternatively, hiPSCs were differentiated following the Carpentier et. al. protocol until 
Day 16 [36]. On day 16 of the protocol, the HLCs were cultured an extra 3 days in the 
“differentiation medium + 107 M DEX” and were then cultured 3 days in the “WEM-based 
maintenance medium” supplemented with 107 M DEX. HLCs were collected on Day 22. 
 
Immunocytochemistry 
Cells were washed with PBS and fixed with 4% paraformaldehyde (Polysciences, 
Warrington, PA) in 1x PBS for 15 minutes prior to staining. When necessary, samples were 
permeabilized in 1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) in PBS for 1 hour at room 
temperature.  Subsequently, all samples were blocked with 5% goat serum (Sigma) in PBS for 
one hour at room temperature. Primary antibodies were diluted to working concentrations in 5% 
goat serum; cells were incubated with the primary antibody overnight in 4°C. After incubation, 
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cells were washed three times with PBS at 5 minutes per wash. Secondary antibodies were 
diluted in 5% goat serum and cells were incubated for 1 hour at RT. Cells were washed three 
times with PBS and incubated with 1X DAPI (Thermo, Waltham, MA) for 7 minutes. 
Fluorescence images were captured with an Axiocam MR Monocolor Camera and AxioVision 
Digital Image Processing Software (Axio Observer Inverted Microscope; Carl Zeiss, Jena, 
Germany). The primary and secondary antibodies used for hiPSC and hepatocyte-like cells are 
listed in Table 1. 
 
Teratoma formation and analysis 
Teratomas for the control and disease hiPSC lines were generated by injecting 1 x 106 
cells (resuspended in Matrigel [BD Biosciences]) subcutaneously into both hind limbs of male 
severe combined immunodeficient (SCID) mice (Charles River Laboratories, San Diego, CA). 
Tumors were harvested roughly 1-1.5 months after injection and fixed in 4% paraformaldehyde. 
Tissues were routinely processed and paraffin-embedded followed by staining with hematoxylin 
and eosin (H&E). All animal experiments adhered to policies set by the UCLA Animal Research 
Committee and the UCLA Division of Laboratory Animal Medicine (Protocol #2006-119-22). 
 
Karyotype analysis 
hiPSCs were cultured to 95-99% confluency in 25 cm2 flasks and delivered to Cell Line 
Genetics, Inc. (Madison, WI) for G-band karyotyping analysis. 
 
Reverse transcription-polymerase chain reaction  
 RNA was extracted from primary fibroblasts, hiPSCs, and hepatocyte-like cells with a 
Roche High Pure RNA Isolation Kit (Roche Applied Sciences, Indianapolis, IN) and 10 ng–1 mg 
was reversed transcribed to cDNA with the Transcriptor First Strand cDNA synthesis kit (Roche 
Applied Sciences) following the manufacturer’s instructions. Primers were designed in 
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NCBI/Primer-Blast and synthesized by Valugene, Inc. (San Diego, CA) and are listed in Table 2. 
RT-PCR was performed with 25 ng of cDNA from each sample and each reaction was prepared 
with 12.5 mL 2x KAPA Fast Genotyping Mix (Kapa Biosystems, Wilmington, MA) and with 10 
mM forward and reverse primers and was run on a LightCycler 480 Real-Time PCR System 
(Roche Applied Sciences). Gels were made with 2% agarose (Bio-Rad Laboratories, Hercules, 
CA) and 1x SYBR Safe DNA Gel Stain (Life Technologies) in tris-acetate-EDTA (TAE) buffer 
and run on a PowerPac Basic Power Supply (Bio-Rad, Hercules, CA) at 90v for 30 minutes.  
 
Quantitative reverse transcription polymerase chain reaction 
Total RNA was isolated from cultures with a Roche High Pure RNA Isolation Kit (Roche 
Applied Sciences) and 250 ng-1 mg was reverse transcribed to cDNA utilizing a Transcriptor 
First Strand cDNA Synthesis Kit (Roche Applied Sciences). Primers for endogenous arginase 
and human codon-optimized arginase and probes (designed from the Roche Universal Probe 
Library) were synthetized at Valuegene Inc. (Table 3). Quantitative PCR relative gene 
expression experiments were performed with 10 ng of cDNA on a LightCycler 480 Real-Time 
PCR System (Roche) and data was analyzed with LightCycler 480 Software (release 1.5.0.). 
Triplicate experimental samples were paired using the all-to-mean pairing rule ΔCt value 
calculation with GAPDH for advanced relative quantification. 
 
Cloning and gene optimization 
pUC18-HPRTx1-LHA-hEF1α-ArgO-IRES-PAC-HPRTx1-RHA was cloned by PCR of 
HPRTx1 (Exon 1)-RHA(Right Homologous Arm) with primers 5-HPRT-RHA-NotI 
(GCATGCGGCCGCCAGTCAGCCCGCGCGCC) and 3-HPRT-RHA-PstI 
(CGATCTGCAGCCTGCCGCCCTCGCGT) and restriction enzyme digested with NotI and PstI. 
HPRTx1-LHA (Left-Homologous-Arm) was synthesized by GeneWiz, removed and isolated from 
pUC57-Kan by digestion with EcoRI and XbaI. hEF1α-ArgO-IRES-PAC was removed and 
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isolated from pRRL-hEF1α-ArgO-IRES-PAC with XbaI+NotI digest. Two synthetic 
polyadenylation sequences [62] were inserted 3' of HPRTx1-LHA and 5' of HPRTx1-RHA by 
cutting and inserting the sequences with SpeI and NotI, respectively.  Oligonucleotides were 
synthesized by ValueGene and annealed together to create inserts for cloning. Finally, all 
inserts were ligated together with pUC18 digested by EcoRI and PstI. DNA was introduced into 
cells by nucleofection (see Supplemental Experimental Procedures for details). 
Human codon optimized arginase (ArgO) was developed by running the amino acid sequence 
of arginase 1 through Gene Designer 2.0 software (DNA2.0, Menlo Park, CA) against the homo 
sapiens codon usage table. Once the initial sequence was produced, it was run through 
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) to find any cryptic splice sites. This 
sequence was then checked for any long repeats in Oligonucleotides Repeat Finder 
(http://wwwmgs.bionet.nsc.ru/mgs/programs/oligorep/InpForm.htm). Any variations needed to 
delete splice sites or long repeats were silent mutations that used the next most common codon 
in the Homo sapiens codon usage table. 
 
Junction PCR and sequencing analysis 
To verify targeted integration of our donor vector in corrected hiPSCs, each 5’ and 3’ 
junction of the integrated vector was analyzed by PCR and DNA sequencing. Reactions were 
prepared with genomic DNA, 12.5 mL of Phusion High-Fidelity PCR Master Mix (New England 
BioLabs, Ipwich, MA), 10.25 mL of water, and 1.25 mL of forward and reverse primers for the 3’ 
and 5’ ends of Exon 1 of HPRT (Table 4).  
 For sequencing, PCR bands were extracted and purified using the Wizard SV Gel and 
PCR Cleanup System (Promega, Madison WI) and the purified products were sent to Laragen 
(Culver City, CA) for sequencing analysis. 
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Off Target Analysis 
To identify potential introduced mutations at other regions in the genome, off-target 
binding/cutting of the DNA by the CRISPR/Cas9 nucleases resulting in insertions or deletions 
(INDELs) was analyzed at the predicted most common sites for each CRISPR/cas9 nickase as 
determined by the MIT CRISPR Design website (crispr.mit.edu). Each corresponding gDNA 
region sequence was downloaded from the PubMed genebank. PCR primers were designed 
using the ThermoFisher primer designer (www.thermofisher.com/oligoperfect.html). Appropriate 
primers were synthesized by Integrated DNA Technologies (Coralville, IA) to amplify each off-
target region. For particularly GC-rich regions, 5% DMSO or Betaine (Sigma) was added. The 
region on the other HPRT allele was amplified using the same 5'F and 3'R junction PCR primers 
as was used for junction PCR analysis. Each potential off-target region was amplified by PCR 
from both the parental and genetically modified gDNA samples of AD1 using the Phusion PCR 
Master Mix (ThermoFisher). PCR conditions were set according to manufacturer 
recommendations: 1. 98C 30s, 2. 98C 10s, 3. 57C 30s, 4. 72C 1min, Repeat 2-4 35x, 5. 72C 5 
min, 6. 4C hold using Phusion high-fidelity PCR master mix (ThermoFisher).  PCR products 
were run on a 1% agarose gel for approximately 20 minutes at 100V. Bands were extracted 
using the Wizard SV Gel and PCR Cleanup System, followed manufacturer protocol and were 
sequenced by Laragen. 
To also determine if both HPRT alleles were integrated with the LEAPR construct, we 
performed quantitative real time PCR (codon-optimized arginase, genomic GAPDH, and 
genomic HPRT) of each AD line knowing that AD1 and AD3 were XX and AD2 was XY. 
Knowing this, we reasoned that we should see twice as much genomic HPRT in AD1 and AD3 
compared to AD2 (Figure S7 top). In addition, we reasoned that we should see the same 
amount of codon-optimized arginase expression in all three AD lines relative to GAPDH (Figure 
S7 middle). Finally, if only one allele was integrated we should detect half as much codon-
optimized arginase expression in AD1 and AD3 compared to AD2, relative to HPRT (i.e. 1 copy 
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of codon-optimized arginase per 2 copies of HPRT in AD1 and AD3 compared to 1 copy of 
codon-optimized arginase per 1 copy of HPRT in AD2) (Figure S7 bottom). 
 
Functional assay for arginase activity 
Arginase activity was measured in cell lysates. 2 x 106–4 x 106 cells were pelleted by 
low-speed centrifugation and frozen for each sample. Cell pellets were lysed at 20,000 cells/mL 
in lysis buffer. Primary tissue sample controls were homogenized with 40 mL of lysis buffer/mg 
of tissue. Lysis buffer was prepared with 0.1% Triton X-100 and 1x HALT protease inhibitor 
cocktail (Thermo) and urea production was measured as previously performed [27, 28]. Briefly, 
samples were centrifuged at 100 x g for 5 minutes at 4°C and the supernatant was collected. An 
activated mixture, consisting of 12.5 mL of 50 mM Tris-Cl (pH 7.5), 12.5 mL of 10 mM MnCl, 
and 25 mL of the supernatant was incubated at 56°C for 10 minutes. 2.5 mL of the activated 
mixture was added to 25 mL of 0.5 M arginine (pH 9.7) and incubated at 37°C for 1 hour. After 
incubation, 72.5 mL ddH2O was added to bring the final volume to 100 mL. 400 mL of an acid 
mixture, consisting of 1 part H2SO4 (95%), 3 parts H3PO4 (85%), and 7 parts ddH2O, in addition 
to 25 mL of 9% isonitrosopropiophenone (ISPF) in ethanol, was added to samples and urea 
standards. Urea standards were prepared at 9.3, 18.7, 37.5, 75, 150, and 300 mg/mL in ddH2O. 
The final mixture was incubated at 100°C for 45 minutes. After incubation, samples were cooled 
to room temperature and protected from light for 10 minutes. 200 mL of each sample was 
aliquoted in duplicate and measured at an optical density of 540 nm in a 96-well plate in a plate 
reader (Bio-Rad). 
 
Sequencing Analysis 
Fibroblasts were cultured in 25 cm2 flasks and delivered to GeneDx (Gaithersberg, MD) 
for complete Arg1 gene sequencing and mutation analysis. Mutations were analyzed in hiPSC 
and hepatocyte progeny in the UCLA Orphan Disease lab by PCR followed by Sanger 
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sequencing. Select regions of the Arg1 gene were amplified by PCR using standard conditions 
(95° for 2 min [1 cycle]); 94° for 30 sec, 60° for 30 sec, 72° for 1 min [35 cycles]; 72° for 3 min [1 
cycle]; hold at 10°). Primer sequences for the c.61C>T variant were as follows: (5’-
TTTGCACAAACTACTTGTTCACTG-3’; 5’-TCAGAGTGGGGAGGAAATCA-3’).  Primers for the 
c.365G>A variant were as follows: (5’-AAAACCAAGTGGGAGCATTG-3’; 5’-
CCTTCCACCTCCTGAATGTC-3’).  Primers for the c.709G>A variant were as follows:  (5’-
CATGAAATAATGGGTTGCTACTTTT-3’; 5’-TTGCTTCTCTATTACCTCAGATTGTT-3’).  
Primers for the c.892G>C variant were as follows: (5’-CCATCGGTTACTACCTTTTTCTG-3’; 5’-
TCTGAAAGAACAAGTCTTTAGAAGG-3’). An aliquot of each PCR product was confirmed by 
gel electrophoresis based on its predicted amplicon size. The rest of the PCR product was 
purified using the QIAquick PCR purification kit (Qiagen) and subjected to bidirectional 
sequencing using ABI BigDye v3.1 terminators on an ABI 3130xl genetic analyzer (Applied 
Biosystems, Foster City, CA). The sequence traces at each location were manually analyzed for 
the presence of a variant using the SequenceScanner v.1 software (Applied Biosystems, Foster 
City, CA) in comparison to the GenBank reference sequence NM_000045.3. 
 
Statistical Analysis 
All collected data was analyzed with the SPSS (Armonk, NY) statistical package 
(Version 21.0). Results were expressed as mean ± standard deviation (SD) and p values were 
determined using a one-way ANOVA to examine significance across comparisons. Error bars 
represent SD. 
 
 
 
 
 
	19 
Results 
Derivation of patient-specific hiPSCs from arginase-deficient dermal fibroblasts 
 We derived genetically-distinct hiPSC lines from dermal fibroblasts taken from three 
patients with hyperargininemia. The first disease dermal fibroblast line, AD1, originating from a 
female argininemic patient, was purchased from Coriell (GM00954). Two additional dermal 
fibroblast lines, AD2 and AD3, were derived from skin punch biopsies obtained from a male and 
female patient, respectively. The AD dermal fibroblasts were successfully reprogrammed to 
hiPSCs using a lentiviral vector expressing a constitutive polycistronic cassette (STEMCCA) 
encoding the four transcription factors OCT4, SOX2, KLF4, and cMyc [54, 60, 63]. Dermal 
fibroblasts were transduced with the STEMCCA lentivirus and were maintained in culture for 30 
days on MEFs before conversion to feeder-free culture conditions. The control hiPSC line 
(xcHUF1), derived from the dermal fibroblasts of a healthy adult male, was previously 
established in the lab using the same reprogramming methodology [59]. 
AD1, AD2, and AD3 hiPSC lines exhibited normal stem cell-like morphology throughout 
the course of the study. Characterization of the AD hiPSCs included immunophenotyping for 
common pluripotent stem cell markers, alkaline phosphatase staining, in vivo teratoma 
formation, and karyotype analysis. AD1, AD2, and AD3 hiPSCs stained positive for pluripotency 
markers: Oct4, NANOG, SSEA-3, SSEA-4, Tra-1-60, Tra-1-81 and all exhibited positive alkaline 
phosphatase activity (Figure 1-1A). AD hiPSCs were collected and injected subcutaneously into 
the hindleg of SCID mice for in vivo teratoma analysis. Teratoma sections from AD1, AD2, and 
AD3 were stained with H&E and exhibited formation of gut (endoderm), neuroectoderm 
(ectoderm), and chondrocyte (mesoderm) derivatives, demonstrating the ability of our hiPSCs to 
form tissues from all three germ layers (Figure 1-1B). Furthermore, normal karyotypic analyses, 
with no genomic abnormalities, were detected through G-banding studies of AD1, AD2, and 
AD3 hiPSC lines (Figure 1-1C). Additionally, the specific arginase mutations were determined 
for each line (Figure 1-1D). Characterization of all three diseased hiPSCs were compared to 
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non-diseased controls as xcHUF1 hiPSCs and demonstrated no difference in pluripotency 
profile (data not shown). 
 
Design of ArgO and vectors for gene correction of hiPSCs 
 To correct for the mutant Arg1 gene in our patient-derived AD hiPSCs, we designed a 
selectable, full-length codon-optimized human arginase cDNA (ArgO) expression cassette 
under the constitutive control of the human elongation factor 1a (hEF1a) promoter, referred to 
as LEAPR (Left homologous arm-hEF1a-ArgO-IRES-Puro(R)-Right homologous arm), to be 
inserted into Exon 1 of the HPRT locus (Figure 1-2A). Utilizing CRISPR/Cas9 nickases to bind 
and cleave Exon 1 of HPRT, we achieved targeted LEAPR addition into this desired site. 
LEAPR addition and disruption of the HPRT locus allowed for secondary positive clonal 
selection of successful on-target integration via resistance to 6-thioguanine (6-TG) treatment. 
Additionally, a puromycin resistance gene encoded within the LEAPR construct afforded the 
ability to utilize an efficient dual selection method to isolate a clonal population of cells that 
successfully integrated our vector into the HPRT locus. After dual selection with puromycin and 
6-TG, AD1, AD2, and AD3 hiPSCs maintained normal stem cell-like morphology (data not 
shown). 
 
Evaluation of Targeted Integration and Expression of ArgO into Corrected hiPSCs 
 After delivery of the LEAPR construct, we performed experiments to verify correct on-
target integration into the AD hiPSCs. AD hiPSCs were first dual-selected by two cycles of 1 
µg/mL puromycin treatment for 72 hours followed by 6-TG treatment. Dual-resistant cell 
populations were then clonally selected into three subclones each for all AD hiPSC lines. To 
analyze the targeted integration of our donor vector into Exon 1 of the HPRT locus, primers 
were designed to span each junction between the endogenous genome and our inserted vector. 
For each junction, one primer was designed to bind a region of the genome outside of the 
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homologous arm region, and another was designed to bind a sequence within our inserted 
donor vector. Products at both 5’ and 3’ junction sites demonstrated on-target integration of our 
LEAPR construct in each of three subclones of the corrected AD1, AD2, and AD3 hiPSC lines 
(Figure 1-2B). Additionally, sequencing analysis of the junction PCR products showed the 
seamless transition between donor vector sequence and the endogenous genome sequence of 
our gene-corrected cell lines at both the 5’ and 3’ junctions of our gene cassette insert (Figure 1-
2C).  
To further characterize the targeted integration of LEAPR into the AD hiPSCs, we 
utilized qRT-PCR to determine whether the LEAPR construct integrated into one or both HPRT 
alleles in corrected AD1 and AD3 LEAPR hiPSCs and also used sequencing technology to 
further examine AD1. As AD1 and AD3 are XX and AD2 is XY, qRT-PCR confirmed and 
demonstrated twice the levels of genomic HPRT (gHPRT) in AD1 and AD3 compared to AD2 
relative to genomic GAPDH (gGAPDH) (Figure 1-S4 top). Furthermore, qRT-PCR demonstrated 
equal amplification of ArgO, a unique element of the LEAPR construct, relative to genomic 
GAPDH demonstrating an equal number of LEAPR integrations throughout the genomes of AD 
LEAPR hiPSCs (Figure 1-S4 middle). Finally, qRT-PCR demonstrated AD1 and AD3 with half 
the level of ArgO compared to AD2, relative to HPRT consistent with the integration of 1 LEAPR 
copy per 2 HPRT alleles in AD1 and AD3 and 1 LEAPR copy per 1 HPRT allele in AD2 (Figure 
1-S4 bottom). We also sequenced the other HPRT allele of AD1 which showed lack of an 
integration, confirming that only one allele had the integrated donor arginase construct. 
However, because of nuclease activity at that site, 5 genetic mutations were introduced in the 
other HPRT allele, the first 4 being silent mutations and the fifth resulting in a serine to 
phenylalanine amino acid change (data not shown). 
Off-target analysis was performed in AD1 LEAPR hiPSCs to determine and quantify 
potential insertions and deletions (INDELs) due to off-target sequence homology for nickases A 
and B. High probability sites for off-target nickase binding for each nuclease were determined in 
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silico (probability scores of 1.37, 0.86, and 0.86 for nickase A and 0.58 and 0.58 for nickase B 
[out of a maximum score of 100]) were examined via sequencing. Analysis demonstrated 0% 
INDELs at all sites (Figure 1-S3A and 1-S3B).  
Arginase levels were examined in the LEAPR-corrected hiPSC lines by measuring RNA 
expression via qRT-PCR and functionality via urea production (i.e. restoring ureagenesis). After 
puromycin and 6-TG selection, corrected hiPSCs (n = 3) expressed significantly higher RNA 
levels (p < 0.001) of codon optimized arginase compared to wild type arginase RNA levels in 
uncorrected AD hiPSCs, demonstrating on-target integration and expression in all three 
corrected hiPSC lines. The integration of ArgO increased arginase mRNA levels in AD1, AD2, 
and AD3 hiPSCs to 57%, 92%, and 46% (replicates of n = 3 per sample) respectively when 
compared to wild type arginase levels in human fetal liver (Figure 1-3A). Additionally, all 
corrected AD hiPSCs exhibited a significant increase (p < 0.001) in urea production itself (i.e. 
functional activity) when compared to their uncorrected counterparts (Figure 1-3B). Functionality 
of corrected AD1 hiPSCs increased to 102% (p = 0.021) of that measured in human fetal liver 
levels (Figure 1-3B). Varying degrees of recovery were observed in AD1, AD2, and AD3 
corrected lines; however, the lowest recorded recovery level was still 71% of the primary fetal 
liver (Figure 1-3B). Taken together, these data demonstrate 1) a high specificity of integration 
into Exon 1 of the HPRT target site as well as 2) a high codon optimized arginase RNA 
expression with substantial functional arginase enzyme activity in hiPSCs. 
 
Directed differentiation of human pluripotent cells into hepatocyte-like cells 
 Using a previously published protocol [38], we differentiated the corrected AD1, AD2, 
and AD3 hiPSCs, their uncorrected counterparts, and control xcHUF1 hiPSCs into HLCs. After 
21 days, we assessed expression of specific liver markers and assessed liver cell-specific 
functions of our derivatives. Morphology of the genetically modified AD1 LEAPR HLCs 
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resembled both that of their uncorrected counterparts (AD1 WT HLCs) and primary human 
hepatocytes (PHHs) (shown in Figure 1-4A; AD2 and AD3 shown in Figure 1-S1A).  
At the end of the final differentiation stage, we characterized the expression of hepatic 
markers in our derivatives. Similar to the PHH control, LEAPR-corrected AD1, AD2, and AD3 
derivatives stained positive for albumin (Figure 1-4A for AD1 and Figure 1-S1A for AD2 and 
AD3). The HLCs exhibited expression of AFP, whereas the PHH control was essentially 
negative for AFP (Figure 1-4A). This observation is consistent with previous studies 
demonstrating that PSC-derived HLCs more closely mimic fetal as opposed to adult 
hepatocytes [64]; that is, mature hepatocytes lose AFP expression while more fetal-like 
hepatocytes continue to express AFP. Therefore, we compared RNA expression of multiple 
hepatic-specific markers of the derivatives to a human fetal liver control. RT-PCR analysis 
showed that AD1, AD2, and AD3 HLCs all expressed hepatic functional genes including: ALB, 
AFP, AAT, CK18, CPS1, CYP3A4, FIX, TF, TDO2, and UDP-GT (Figure 1-4B for AD1 and 
Figure 1-S1B for AD2 and AD3). PHHs and fetal liver were used as positive controls for the 
immunostaining and RT-PCR analysis, respectively. 
Additionally, we assessed liver-specific functionality of both our genetically modified and 
unmodified AD1, AD2, and AD3 HLCs. At day 21, we measured glycogen storage via Periodic 
Acid-Schiff (PAS) staining of all hepatic derivatives. Similar to PHHs, corrected AD1, AD2, and 
AD3 HLCs stained positive by PAS (Figure 1-4A for AD1 and Figure 1-S1A for AD2 and AD3). 
These results demonstrate that genetic modification of hiPSCs with our LEAPR construct does 
not interfere with the capability of the cells to differentiate into HLCs. 
 
Evaluation of arginase expression and functionality in hepatocyte-like cells 
We examined codon optimized arginase RNA expression and functionality in the hiPSC-
derived HLCs to determine the maintenance of arginase expression after directed 
differentiation. After the final differentiation step, RNA was collected from LEAPR-corrected 
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AD1, AD2, and AD3 HLCs and arginase levels were quantified and compared to both corrected 
hiPSC and fetal liver levels via qRT-PCR. Hepatic differentiation did result in a decrease in 
arginase RNA expression in all three LEAPR-corrected HLC lines compared to undifferentiated 
hiPSCs (p < 0.001 for AD1, AD2 and AD3) (Figure 1-5A). However, despite the decline in RNA 
expression compared to hiPSCs, AD1, AD2, and AD3 HLCs maintained arginase levels of 27%, 
39%, and 36% of fetal liver Arg1 levels (AD1, AD2, and AD3 respectively). 
Next, we determined if targeted integration of the LEAPR construct affected expression 
of the wild type mutated arginase and other endogenous urea cycle-specific genes in the 
hepatocyte-like cells, specifically, carbamoyl phosphate synthase 1 (CPS1), which catalyzes the 
synthesis of carbamoyl phosphate from glutamine. We measured mRNA levels of CPS1 in both 
uncorrected and corrected hiPSCs and HLCs (Figure 1-S2). Similar to wild-type mutated 
arginase mRNA expression, CPS1 levels were significantly increased post-differentiation in both 
uncorrected and corrected lines (p < 0.01 for AD1 uncorrected lines; p < 0.001 for AD1 
corrected, AD2 uncorrected and corrected, and AD3 uncorrected and corrected lines). These 
data suggest that the increasing arginase expression with our LEAPR construct in the disease 
lines does not negatively impact the expression of other endogenous urea cycle-specific genes. 
With the above decline in RNA expression, there was an expected post-differentiation 
decline observed in ureagenesis of the LEAPR derivatives (p < 0.001 for AD1 and AD3; p = 
0.001 for AD2 compared to corrected hiPSCs). Importantly, though, all three corrected HLC 
lines maintained greater than 40% of the level of urea production (i.e. arginase activity) of fetal 
liver (Figure 1-5B). 
 
Optimization of ArgO-expressing vectors 
 Additional efforts to develop optimized ArgO-expressing vectors with the purpose to 
better maintain ArgO expression in post-differentiated LEAPR derivatives were explored. The 
minimal ubiquitous chromatin opening element (UCOE) has been shown to prevent silencing of 
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heterologous promoters in human pluripotent stem cells in lentiviral vectors [65]. Therefore, we 
cloned an expression cassette encoding ArgO driven by the UCOE and hEF1α promoter 
(LEAPR+UCOE) combination similarly designed for CRISPR/Cas9 nickase-mediated 
homologous recombination targeted to exon 1 of HPRT (Figure 1-6A). Though ArgO RNA 
expression significantly increased after differentiation to HLCs in AD1 hiPSCs modified with the 
LEAPR+UCOE vector, a similar significant decrease in functionality compared to the LEAPR 
vector was observed (Figure 1-6B-C). 
 
Optimization of HLC differentiation protocols 
 Though HLCs obtained from the Song et. al. protocol yielded hepatic-like gene 
expression as examined by ICC and RT-PCR, upon further examination by qRT-PCR, albumin 
expression was low compared to human fetal liver controls (data not shown). In order to obtain 
more mature HLCs, protocol modifications and additional protocols were examined. Efforts were 
made to modify Song et. al. protocol by optimization of definitive endoderm induction that 
improved differentiation, but did not yield appreciable increases in albumin expression (data not 
shown). HLCs were derived using a modified version of a protocol developed by Carpentier et. 
al. and compared to Song et. al. HLCs [36]. Carpentier et. al. HLCs yielded improved hepatic 
morphology and gene expression profiles as demonstrated by significantly increased levels of 
CPS1 and FAH RNA, but still did not yield high levels of ALB and similar levels of AFP RNA 
(Figure 1-7A-E). Further modifications of Carpentier et. al. HLCs including use of laminin 
basement substrates additionally did not improve albumin expression (data not shown).  
Carpentier et. al. HLC gene expression was further examined by qRT-PCR and 
compared to human fetal liver controls and primary human hepatocytes (PHHs). Carpentier et. 
al. HLCs demonstrated significantly higher levels of AFP and significantly lower levels of ALB 
RNA compared to fetal liver and PHHs, but demonstrated similar levels of FAH compared to 
fetal liver (Figure 1-8A-C). Supernatant was collected over the duration of the differentiation 
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protocol and demonstrated significant increases of secreted albumin over time culminating in 
3730 ng/mL of secreted albumin on D22 (Figure 1-8D). Therefore, though RNA levels as 
assessed by qRT-PCR were low compared to fetal liver and PHHs, secretion of albumin protein 
was comparable if not higher than the published protocol. Urea cycle enzymes were also 
assessed and demonstrated a general trend toward a fetal-like profile (Figure 1-8E-K). 
Therefore, though the current HLC differentiation protocol still produces HLCs with an overall 
fetal-like profile, the modifications have indicated a step toward hepatic maturity. 
  
Development and examination of an AFP-Reporter/Selection Construct for hepatocyte isolation 
 The derivation of hiPSCs initiated a push for elucidating the molecular cues to 
differentiate hepatic lineages for development of patient-specific cell replacement therapeutics 
for liver and metabolic diseases. Though several groups have derived HLCs demonstrating 
appropriate phenotypic, morphological, and functional characteristics, inefficiency of derivation, 
inherent line-to-line variation, and risk for lingering potentially tumorigenic pluripotent stem cells 
in post-differentiated cultures remain common issues of concern for clinical applications. AFP is 
a major plasma protein produced by the liver and hepatocytes during fetal development and is 
not expressed in hiPSCs. Additionally, AFP+ cells derived from hepatic differentiation protocols 
have been demonstrated to engraft and further mature upon in vivo transplantation [66, 67]. We 
developed a preclinical reporter/selection vector (ARC) encoding an AFP enhancer and 
promoter driving expression of fluorescent protein tdTomato and blasticidin resistance aimed to 
isolate AFP+ HLCs from post-differentiated cultures via FACS-Sort and/or in vitro antibiotic drug 
resistance selection (Figure 1-9A). The ARC allows for integration into the adeno-associated 
virus integration site 1 (AAVS1) safe harbor locus, a widely studied safe harbor site that permits 
long-term transgene expression [68]. Therefore, we aimed to determine if modifying AD hiPSCs 
with ARC and post-differentiation selection would lead to populations of HLCs of higher hepatic 
expression and higher potential for engraftment.  
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 H9 embryonic stem cells (ESCs) were first used to optimize the vector and selection 
protocols. H9 ESCs were nucleofected with the ARC vector with CRISPR/Cas9 nickases 
specific for in-frame integration into the AAVS1 safe harbor locus. After purification, clonal 
expansion, and differentiation into HLCs under established protocols, HLCs were treated with 
1.25 µg/mL blasticidin for 72hrs and tdTomato+ populations were quantified via flow cytometry 
to be 84% while unselected populations were 81% tdTomato+ (Figure 1-9B). Though 
tdTomato+ enrichment levels have reached up to 89.3% in other experimental runs, blasicidin 
treatment caused loss of hepatic morphology and gene expression profile as assessed by qRT-
PCR compared to the untreated control (Figure 1-9C-F). However, sorting tdTomato+ HLCs 
through FACS does maintain/improve hepatic gene expression profile compared to the 
untreated control (Figure 1-9D-F). Though there is a modest improvement of hepatic gene 
expression after sorting for tdTomato+ HLCs via FACS, this strategy would not be scalable for 
future clinical applications.  
 
Transplantation of pluripotent stem cell-derived HLCs 
 To determine in vivo efficacy of gene-added hiPSC-derived HLCs for treatment of 
arginase deficiency, our group established and characterized an immunosuppressed arginase 
deficient mouse model (FRG-CKO) [69]. In order to demonstrate this model as an appropriate 
model for upcoming HLC transplantations, PHHs were transplanted by intrasplenic injection and 
allowed to engraft and repopulate the liver. After the endogenous murine arginase function was 
disrupted, we demonstrated that the PHH-transplanted mice controlled normal plasma ammonia 
levels, amino acid profiles, could withstand an exogenous ammonia load, and maintained 
normal neurological behavior. These studies demonstrated that human hepatocyte repopulation 
in the murine liver can result in effective treatment of arginase deficiency.  
  Transplantation of HLCs have been attempted with no success. Using the Song et. al. 
HLC differentiation protocol, 1x106 D21 HLCs derived from AD1 uncorrected (n = 4), AD1 
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LEAPR C1 (n = 5), AD1 LEAPR C3 (n = 5), and xcHUF1 control hiPSC (n = 8) were 
transplanted and did not engraft within the liver of FRG-CKO mice leading to death of FRG-CKO 
mice either during NTBC cycling or after knockout of endogenous arginase. Additionally, D10 
HLCs from AD1 LEAPR C3 (n = 10) and D5 definitive endoderm from xcHUF1 (n = 6) were also 
transplanted and did not engraft. Using the optimized Carpentier et. al. differentiation protocol, 
we transplanted 1x106 D23 HLCs derived from H9 ESCs (n = 5) and could not detect circulating 
human albumin by D56 indicating a lack of expansion of the transplanted HLCs.  
 
Discussion 
Chronic therapy for urea cycle disorders includes dietary restriction to limit nitrogen 
intake and pharmacological intervention with nitrogen scavenging drugs (e.g. phenylbutyrate). 
Such substrate restriction is commonly used for treating urea cycle disorders and while it is 
somewhat effective, this is more prophylactic than curative and patients remain at risk for 
developing long-term neurological issues due to intermittent hyperammonemia. Gene and stem 
cell therapy have emerged as promising therapeutic avenues to treat these disorders and 
prevent the development of hyperammonemia-induced neurological injury [26, 70-73].  
Stem cells, specifically hiPSCs, provide an almost inexhaustible source of patient-
specific cells that can undergo directed differentiation into various somatic cell types to be used 
for cellular replacement therapies [74-76]. Due to their therapeutic potential, considerable effort 
has been aimed into optimizing protocols to genetically modify these cells in order to model 
diseases and to use in potential cellular therapies [77]. However, despite the promise of utilizing 
genetically modified hiPSCs for therapeutic studies, the ability to efficiently deliver genes to 
targeted sites in hiPSCs is hampered by several challenges. Non-viral methods, such as 
chemical transfection or electroporation, and viral methods, via lentiviruses or adeno-associated 
virus (AAVs), all suffer from relatively low transfection and transduction efficiencies, transient 
expression, and off-target integration in the host hiPSC genome [70, 77]. Recently, the 
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development of highly specific clustered interspaced short palindromic repeats (CRISPRs) and 
CRISPR-associated (Cas) systems to introduce genes into hiPSCs have begun to address 
many previous issues surrounding genomic editing of stem cells. Unlike its predecessors, such 
as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), 
CRISPR/Cas9 systems can be produced rapidly and introduced into specific target sites with 
increased accuracy [58, 78, 79]. As such, recent studies have demonstrated highly efficient 
genetic correction of hiPSCs utilizing CRISPR/Cas9 for neural and muscular disorders [46]. 
The goal of the present study was to determine if integration of codon-optimized 
arginase into three genetically distinct patient-specific hiPSCs could produce in vitro enzyme 
function after differentiation into hepatocyte-like derivatives for potential use in cellular therapy 
for these patients. Previous gene therapy studies have demonstrated successful reversal of 
disease manifestations through either treatment of neonatal mice with a helper-dependent 
adenoviral vector (HDV) [26] or with AAV-expressing arginase [27]. In the former, the transient 
nature of expression led to loss of arginase function while in the later, long-term survival without 
neuropathology was achieved; however, with the loss of episomal AAV genomes, the level of 
arginase expression was low and, therefore, the animals remained nitrogen vulnerable [80]. 
However, these murine studies were able to determine that long-term survival [27] with normal 
behavior and learning [81] was possible and that only low levels of hepatic arginase activity, as 
low as 3.5-5%, were necessary to prevent brain injury and/or death from hyperammonemia or 
hyperargininemia [80]. Here, we developed a CRISPR/Cas9-based strategy to deliver a codon-
optimized version of human arginase 1 into hiPSCs derived from patients with arginase 
deficiency. Arginase 1 was introduced into Exon 1 of the HPRT locus via a construct containing 
right and left homologous arms, the human elongation factor 1a promoter, a polyadenylation 
signal, and puromycin for selection (LEAPR), resulting in substantial arginase enzymatic activity 
in hiPSCs and in differentiated derivatives. 
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Cellular HPRT is an enzyme that catalyzes the conversion of hypoxanthine to inosine 
monophosphate and guanine to guanosine monophosphate in the non-essential purine salvage 
pathway [82]. Homozygous loss of HPRT function results in Lesch-Nyhan syndrome, which 
causes an overproduction of uric acid. However, in normal conditions, purine salvage and HPRT 
do not play a major role in cell growth and proliferation [83]; in therapeutic administration of cells 
where HPRT is not functional in the large mass of HPRT-positive cells (such as the liver), it is 
believed that this loss will be inconsequential in purine metabolism. There are certainly 
desirable selective advantages of utilizing HPRT for integrated cell selection: HPRT-positive 
cells are sensitive to 6-thioguanine (6-TG), killing cells by post-replicative mismatch repair [84]; 
additionally, this mechanism allows for secondary selection with 6-TG after HPRT locus 
disruption [85, 86]. As transfection efficiency of hiPSCs is inherently low, the incorporation of a 
dual selection method with puromycin and 6-TG allowed us to purify a population of hiPSCs that 
contained the integrated construct at the targeted site utilizing nucleofection to deliver 
CRISPR/Cas9 nickases and the LEAPR cassette. In culture, these corrected hiPSCs showed 
that they maintained proper morphology and pluripotency, and sequencing data and qRT-PCR-
based genomic integration quantification confirmed that the constructs integrated into the 
correct targeted site in a single HPRT allele with no off-target INDELs at high unrelated 
probable sites. While the data demonstrate that a single X chromosome of each AD line is 
integrated with the donor construct, we did detect genetic mutations in the other allele of HPRT 
at the site of nuclease A and B activity. 
Importantly, arginase was highly expressed in LEAPR-corrected cells as shown by both 
qRT-PCR and in urea production from functional arginase activity. After directed differentiation 
of LEAPR-corrected hiPSCs to the hepatic lineage using the Song et. al. protocol, the HLCs 
were positive for albumin and AFP, stored glycogen, and expressed multiple liver-specific 
RNAs. However, after further hepatic profiling by qRT-PCR, HLCs derived from Song et. al. 
strongly exhibited fetal-like characteristics. Therefore, efforts were made to optimize the HLC 
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differentiation protocol where the current protocol is a modified version of Carpentier et. al. 
Though current HLCs are generally still fetal-like, they are a significant improvement upon the 
previous generation.  
To determine if differentiation affected expression and functionality of arginase in the 
hepatocyte-like cells, we quantified RNA levels and urea production for comparison with their 
hiPSC counterparts. While RNA levels of LEAPR-derived arginase in HLCs were lower when 
compared to their hiPSC counterparts, functional arginase expression with urea production for 
all LEAPR-corrected hepatocyte-like cells remained, and at levels that were previously 
determined (with AAV-based gene therapy) to be necessary for arginase-deficient mice to 
survive and be without neurodevelopmental abnormalities. As previous studies by others have 
shown a decline in transgene expression during differentiation with the use of the hEF1a 
promoter in embryonic stem cells [87], this in part may explain the decline in expression in the 
hepatocyte derivatives in this study. Additionally, comparison of wild type mutated arginase and 
CPS1, another urea cycle enzyme, demonstrated that LEAPR modification does not negatively 
affect the expression of endogenous promoters of urea cycle enzymes. In aggregate, however, 
these data demonstrate that genetic modification at the HPRT locus of the arginase-deficient 
lines had no deleterious effect on their pluripotent capability and overall “stemness”; were not 
altered by nucleofection, selection, or culture of the hiPSCs; and were able to be differentiated 
into hepatocytes with restoration of arginase activity and ureagenesis. 
 Based on these data, integration of arginase 1 via the LEAPR expression construct by 
targeting the HPRT locus demonstrates the potential for restoring enzymatic activity in cells 
derived from hyperargininemic patients. Previously, we have shown in a murine model that with 
relatively low overall hepatic arginase activity establishing ureagenesis at 3.5-5% of normal led 
to long-term survival with controlled plasma arginine and ammonia; however these animals 
remained nitrogen vulnerable due to the low level of arginase expression [80]. LEAPR-corrected 
HLCs across all three lines demonstrated functionality of at least 40% compared to fetal liver; 
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while the hEF1a promoter-based expression, both alone and in combination with the UCOE, did 
decline with cellular differentiation, arginase expression in our studies remains well above the 
minimum threshold needed for survival and adequate nitrogen metabolism determined from the 
prior murine arginase studies [80]. While our present LEAPR construct contains a copy of the 
selection marker puromycin, an aminonucleoside antibiotic, before clinical applicability alteration 
of our donor construct to avoid integration of an antimicrobial resistance gene and the potential 
immunogenicity would be required. This would be accomplished by altering our donor construct 
by adding flanking loxP sites to the puromycin cDNA such that it could excised at the hiPSC 
stage prior to differentiation to the hepatocyte lineage. 
Over the last 30 years, multiple studies including our own for treatment of arginase 
deficiency, in rodents have shown that adult hepatocyte transplantation can reverse liver failure 
and can correct various metabolic deficiencies of the liver [69, 88, 89]. While clinical trials of 
hepatocyte transplantation have demonstrated the long-term safety of cellular administration, 
only partial correction of metabolic disorders in humans has ever been achieved [90, 91]. In part 
due to the limited availability of fresh donor hepatocytes of adequate quality, clinical trials, 
however, have been hampered and reports have been limited in general to case reports 
involving a few patients at most and generally with no untreated controls [92-95]. While attaining 
adequate engraftment will need further attention to make such therapies successful for patients 
with metabolic liver disorders, issues of cellular rejection should be greatly reduced [89] with an 
hiPSC approach as described herein. 
In choosing this approach where cell availability and numbers of hepatocytes will not be 
a limitation, there are other important implications for treating more common monogenic 
disorders of the liver. The safe harbor of exon 1 of HPRT could be used in that the efficiency of 
homologous recombination has been demonstrated here as well as the exogenous gene 
expression at this locus based on the hEF1a promoter. Targeted therapy of other liver-based 
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disorders would be easily addressed by substitution of the arginase cDNA from the donor 
construct with one of the other enzyme cDNA sequences from another metabolic disorder. 
This study presents an approach that can be utilized to integrate an optimized cassette 
into a universal site distant from proto-oncogenes in patient-specific hiPSCs to restore function 
of abnormal liver enzymes. While we have addressed the restoration and maintenance of 
transgene expression pre- and post-differentiation, additional studies aimed to repopulate the 
liver of an established an immunosuppressed conditional arginase deficient mouse model 
capable of liver repopulation of human primary hepatocytes with corrected hiPSC-derived 
hepatic-like derivatives have so far been unsuccessful. Therefore, additional studies are 
required to investigate the in vivo therapeutic efficacy of the corrected derivatives to maintain 
recovered arginase activity after cellular transplantation. However, successful in vivo recovery of 
enzyme function by means of these strategies has the promise to benefit enzyme deficiencies of 
the urea cycle and other inborn errors of metabolism. 
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Figure 1-1. Characterization of arginase deficient (AD) hiPSCs. (A) Pluripotency of all three 
AD hiPSC lines was measured via immunophenotyping. AD1, AD2, and AD3 subclones were 
positive for octamer-binding transcription factor-4 (OCT3/4), homeobox protein nanog 
(NANOG), stage-specific embryonic antigens 3 (SSEA-3) and 4 (SSEA-4), tumor-related 
antigens 1-60 (TRA-1-60) and 1-81 (TRA-1-81), and alkaline phosphatase. AD hiPSCs were 
compared to a wild type hiPSC line xc-HUF1. (Scale bars for all images are 200 mm except 
alkaline phosphatase which is 500 mm.) (B) AD1, AD2, and AD3 hiPSC lines exhibited normal 
46 XX or 46 XY karyotypes, and (C) demonstrated the ability to form tissues from all three germ 
layers: gut (endoderm), chondrocytes (mesoderm), and neuroectoderm (ectoderm). (Scale bars 
= 200 mm) (D) Sequencing analysis reveals specific arginase mutations in each line.  
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Figure 1-2. Design and integration of LEAPR expression cassette. (A) Design of the 
LEAPR construct containing the human codon optimized arginase (ArgO). (B) Junction PCR 
was performed to determine integration of the construct in both wild-type xcHUF1 and AD1, 
AD2, and AD3 hiPSCs in Exon 1 of the HPRT site. (C) Sequencing analysis was performed on 
the integration of the construct in AD1, AD2, and AD3 hiPSCs at the target site.  
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Figure 1-3. Measuring ArgO in AD hiPSCs. (A) Relative gene expression of ArgO, measured 
against glyceraldehyde 3-phosphate dehydrogenase (GAPDH), in AD1, AD2 and AD3 
uncorrected and corrected hiPSCs was measured by qRT-PCR in technical triplicate (n = 3). (B) 
After integration of ArgO in AD hiPSCs, urea production was measured and compared to fetal 
liver (n = 2). Functionality experiments were performed in technical duplicate. (Data are 
represented as mean ± SD.) 
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Figure 1-4. Characterization of hepatocyte-like cells (HLCs). (A) Derived uncorrected and 
corrected (gene added) AD1 HLCs were examined and morphology compared to primary adult 
hepatocytes in vitro (Scale bars = 500 mm). (B) Hepatic markers were examined via RT-PCR in 
uncorrected and corrected AD1 HLCs: alpha 1-antitrypsin (AAT), AFP, human serum albumin 
(ALB), cytokeratin 18 (CK18), carbamoyl phosphate synthase 1 (CPS1), cytochrome p450 3A4 
(CYP3A4), factor IX (FIX), transferrin (TF), tryptophan 2,3-dioxygenase (TDO2), and uridine 
diphosphate glucuronyltransferase (UDP-GT).  
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Figure 1-5. Measuring ArgO in AD hepatocyte-like cells (HLCs). (A) Relative gene 
expression of ArgO, measured against glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
in AD1, AD2 and AD3 corrected hiPSCs and HLCs was measured by qRT-PCR in technical 
triplicate (n = 3). (B) Urea production was measured and compared to fetal liver (n = 2). 
Functionality experiments were performed in technical duplicate. (Data are represented as 
mean ± SD.) 
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Figure 1-6. Design and expression of LEAPR+UCOE expression cassette compared to 
LEAPR expression cassette. (A) Design of the LEAPR+UCOE construct containing the ArgO 
driven by hEF1a and ubiquitous chromatin opening element (UCOE) promoters. (B) Relative 
gene expression of ArgO, measured against glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), in AD1 uncorrected, AD1 LEAPR and AD1 LEAPR+UCOE hiPSCs and HLCs was 
measured by qRT-PCR in technical triplicate (n = 3). (C) Urea production was measured and 
compared to fetal liver (n = 2). Functionality experiments were performed in technical duplicate. 
(Data are represented as mean ± SD.) 
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Figure 1-7. Comparison of hepatocyte-like cell (HLC) differentiation protocols. (A) HLCs 
were generated from the Song et. al. and Carpentier et. al. protocols and morphology was 
compared in vitro (Scale bars = 100 µm). Relative hepatic gene expression, measured against 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was measured via qRT-PCR in Song et. 
al. and Carpentier et. al. HLCs in technical triplicate (n = 3): (B) alpha-feto protein (AFP), (C) 
human serum albumin (ALB), (D) carbamoyl phosphate synthase 1 (CPS1), and (E) 
fumarylacetoacetate hydrolase (FAH).  
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Figure 1-8. Hepatic gene expression profile of Carpentier et. al. hepatocyte-like cells. 
Relative hepatic gene expression, measured against glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), was measured via qRT-PCR in Carpentier et. al. HLCs in technical 
triplicate (n = 3) and compared to human fetal liver and primary human hepatocyte controls: (A) 
alpha-feto protein (AFP), (B) human serum albumin (ALB), (C) fumarylacetoacetate hydrolase 
(FAH). (D) Supernatant throughout the Carpentier et. al. HLC differentiation protocol was 
collected and secreted human albumin was measure via ELISA. Relative urea cycle enzyme 
gene expression, measured against GAPDH, was measure via qRT-PCR Carpentier et. al. 
HLCs in technical triplicate (n = 3): (E) carbamoyl phosphate synthase 1 (CPS1), (F) ornithine 
transcarbamoylase, (G) argininosuccinate synthetase (ASS), (H) argininosuccinate lyase (ASL), 
(I) arginase 1 (ARG1), (J) ornithine translocase (ORNT1), and (K) solute carrier family 25, 
member 13 (CITRIN).  
	42 
 
Figure 1-9. Examining the AFP-Reporter/Selection Construct (ARC) for hepatocyte-like 
cell isolation. (A) Design of the ARC containing an alpha-fetoprotein (AFP) promoter and 
enhancer driving expression of tdTomato and blasticidin resistance. (B) Flow cytometry was 
performed on unmodified HLCs (WT Control) and ARC-modified HLCs treated with blasticidin 
for 72 hrs (Blasticidin-Treated) and untreated (Untreated Control). Percentage illustrates percent 
of tdTomato-positive HLCs in the population. (C) ARC-modified HLCs untreated and treated 
with blasticidin were examined for tdTomato fluorescence intensity and morphology. Relative 
hepatic gene expression, measured against glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), was measured via qRT-PCR for (D) alpha-feto protein (AFP), (E) human serum 
albumin (ALB), and (F) carbamoyl phosphate synthase 1 (CPS1). 
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Figure 1-S1A. Characterization of AD2 and AD3 hepatocyte-like cells. Derived uncorrected 
and corrected AD1 hepatocyte-like were compared to primary adult hepatocytes in-vitro. 
Hepatocyte-like cells were examined for albumin, alpha-fetoprotein (AFP), and active glycogen 
storage, as measured by Periodic Acid Schiff (PAS) staining. (Scale bars = 500 mm)  
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Figure 1-S1B. Characterization of AD2 and AD3 hepatocyte-like cells. Both uncorrected 
and corrected AD1 hepatocyte-like cells were examined for expression of hepatic markers: 
alpha 1-antitrypsin (AAT), alpha fetoprotein (AFP), human serum albumin (ALB), cytokeratin 18 
(CK18), carbamoyl phosphate synthase 1 (CPS1), cytochrome p450 3A4 (CYP3A4), factor IX 
(FIX), transferrin (TF), tryptophan 2,3-dioxygenase (TDO2), and uridine diphosphate 
glucuronyltransferase (UDP-GT). (Mutant refers to endogenous arginase 1 alleles; gene-added 
refers to CRISPR/Cas9-mediated codon-optimized gene addition.) 
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Figure 1-S2. Measuring Wild-type Arg1 and CPS1 levels in uncorrected and corrected 
hiPSCs and hepatocytes. (A) Wild-type Arginase and (B) CPS1 mRNA levels were measured 
in corrected and uncorrected AD1, AD2, and AD3 hiPSCs (n = 3) and hepatocyte-like cells (n = 
3) to determine if genetic modification with LEAPR affected the wild-type Arginase and other 
urea cycle enzymes (Data are represented as mean ± SD)     
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Figure 1-S3A. Off target analysis of nickase A for potential insertions or deletions. 
Sequencing analysis was performed of the three highest probability sites for off-target mutation 
related to nuclease A. All three sites showed no insertions or deletions. 
 
Figure 1-S3B. Off target analysis of nickase B for potential insertions or deletions. 
Sequencing analysis was performed of the highest probability sites for off-target mutation 
related to nuclease B. These sites showed no insertions or deletions.  
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Figure 1-S4. Determining single integration of LEAPR into HPRT locus in corrected 
hiPSCs. Relative genomic integrations of LEAPR into the HPRT locus (located on X 
chromosome) were determined by qRT-PCR (in technical triplicate [n = 3]). Top graph (control) 
confirmed 2:1 ratio of gHPRT levels (relative to gGAPDH) in AD1 and AD3 (female, XX, i.e. 2 
HPRT alleles) compared to AD2 (male, XY, i.e. 1 HPRT allele). Middle graph showed 1:1 ratio 
of ArgO (relative to gGAPDH) in AD1 and AD3 compared to AD2 demonstrating equal number 
of LEAPR integrations in the whole genome. Bottom graph showed 1:2 ratio of ArgO (relative to 
gHPRT) in AD1 and AD3 compared to AD2 demonstrating 1 LEAPR copy per HPRT allele 
(AD1, AD3 = 1 LEAPR copy/2 HPRT alleles; AD2 = 1 LEAPR copy/1 HPRT allele). (Data are 
represented as mean ± SD)  
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CHAPTER 2: Lipid Nanoparticle Targeted mRNA Therapy as a Treatment for the Inherited 
Metabolic Liver Disorder Arginase Deficiency 
 
Introduction 
 With the development of transgenic technology and the advances of the last two and a 
half decades in the progress and application of gene therapy to monogenic disorders of the 
liver, our group has been successful in the development of a mouse model of hyperargininemia 
[25] along with the pre-clinical application of viral-based gene therapy approaches in treating 
this enzyme deficiency [26-28]. The beginning of therapy before [96, 97] or shortly after birth 
[98, 99], before the onset of phenotypic disease, has advantages as early gene therapy has the 
potential to ameliorate genetic abnormalities before the development of phenotypic disease. For 
example, initiating therapy shortly after birth has demonstrated that both restoring hepatic 
arginase activity and controlling hyperargininemia and guanidino compounds leads to normal 
neurological development, cognitive activity and behavior in Arg1-deficient mice [81, 100]. 
However, such therapy with episomal viral vectors [as adeno-associated virus (AAV) 
typically only integrates at a low frequency [101]] is faced with greater challenges in rapidly-
dividing tissues and organs than therapy of post-mitotic tissues [102]. In neonates, the rate of 
hepatocellular proliferation is much higher and affects the maintenance of episomal vector 
genomes [103, 104] while rapid cellular proliferation in adults is uncommon. For example, 
individual hepatocytes in the adult mouse liver are replaced once every 180 to 400 days [105, 
106] while the neonatal murine liver increases from 50 mg to over one gram in the first 5 
postnatal weeks [102]. When administered to neonatal mice this results in a decline in AAV 
copy number of over 3 logs [102] leaving relatively few arginase-expressing hepatocytes long-
term in adult animals and the potential for nitrogen vulnerability [27, 28]. While enzyme 
replacement has led to successful therapies for a number of other genetic disorders, when 
tested in arginase-deficient mice, plasma arginine was reduced [19]; however, repeat dosing did 
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not result in improved survival or prevention of weight loss likely due to the inability of the 
PEGylated enzyme to enter hepatocytes. Additionally, hepatocyte transplantation, though 
demonstrated to be effective in a murine model of arginase deficiency [69], if sourced from 
patient-specific genetically modified pluripotent stem cell-derived hepatic-like derivatives, would 
suffer from lengthy preparation time where patients are at continued risk for progressive 
intellectual decline. Thus, today, there remains an unmet need for these patients. 
mRNA therapy with nanoparticle encapsulation for systemic delivery to hepatocytes has 
the potential to restore metabolic enzymatic activity for a number of hepatic metabolic disorders 
[107, 108] including arginase deficiency. Until recently, RNA-based therapeutics have suffered 
from problems of poor translatability, lack of stability, immune responses, hepatotoxicity [109] 
and inefficient delivery [107, 110]. Recent advances have improved the stability and 
translatability of RNAs and have made them immunologically inactive [107]. While the 
advantages include avoidance of insertional mutagenesis and lack of constitutive gene 
activation, the use of mRNA technology may also allow for restoration of inaccessible targets 
[108] such as cytoplasmic arginase activity that was unachievable with PEGylated enzymatic 
therapy [19]. 
In this study we encapsulated and systemically administered human codon-optimized 
ARG1 mRNA to a conditional knockout murine model of arginase 1 deficiency. We achieved 
delivery of mRNA to the liver by lipid nanoparticles at therapeutic levels in this preclinical model. 
We successfully demonstrated high-level hepatic arginase expression and function with 
restoration of ureagenesis while achieving long-term survival, maintenance of weight, 
normalization of plasma ammonia and arginine, lack of hepatic guanidinoacetic acid (GAA) (a 
guanidino compound) and normalization of hepatic arginine without evidence of hepatotoxicity. 
These findings demonstrate the efficacy of this approach in arginase deficiency. 
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Materials and Methods 
Mouse procedures 
Conditional arginase deficient mice on the C57BL/6 background (Jax Stock number 008817) 
were housed under specific pathogen-free conditions with food and water provided ad libitum. 
All mice were kept according to National Institute of Health guidelines and all experimental 
procedures were conducted in accordance with guidelines for the care and use of research 
animals at our institution. At day 0, 8-12 week old animals were intravenously (IV) administered 
2.0 x 1011 genome copies of AAV8-thyroxine binding globulin (TBG)-Cre recombinase 
(University of Pennsylvania Vector Core, Philadelphia, PA) prepared in sterile pharmaceutical 
grade saline. Male and female mice were distributed evenly throughout the study unless 
otherwise stated. Scheduled blood collections were taken from the retro-orbital plexus under 
isoflurane anesthesia. Plasma was frozen immediately and stored at -80°C. Mice were 
euthanized if they showed symptoms of lethargy, lying on side, or inability to right themselves as 
signs of hyperammonemia. Beginning day 14 post-AAV8-TBG-Cre recombinase injection, mice 
were administered IV lipid nanoparticle-encapsulated (LNP)-mRNA prepared at 2 mg/kg in 
sterile phosphate buffered saline (PBS). One group of mice was injected with LNP-mRNA 
weekly while two groups were injected every 3 days, one of which also received daily LNP-
mRNA loading from day 14 to 21. 
 
mRNA Synthesis and Formulation  
hARG1 mRNA codon optimization was performed using typical methods in the field  [111]. The 
mRNAs encoding luciferase (luc) and hA RG1 were synthesized in vitro by T7 RNA polymerase-
mediated transcription using a linearized DNA template that incorporated both the 5’ and 3’ 
untranslated regions with a poly-A tail and then purified and formulated for intravenous delivery 
as previously described [112]. The open reading frame for hARG1: 
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AUGAGCGCCAAGAGCCGGACCAUCGGCAUCAUCGGCGCCCCCUUCAGCAAGGGCC
AGCCCCGGGGCGGCGUGGAGGAGGGCCCCACCGUGCUCCGCAAGGCCGGCCUCCU
CGAGAAGCUCAAGGAGCAGGAGUGCGACGUCAAGGACUACGGCGACCUCCCCUUC
GCCGACAUCCCCAACGACUCCCCCUUCCAGAUCGUCAAGAACCCCCGCUCCGUCGG
CAAGGCCUCCGAGCAGCUCGCCGGCAAGGUCGCCGAGGUCAAGAAGAACGGCCGC
AUCUCCCUCGUCCUCGGCGGCGACCACUCCCUCGCCAUCGGCUCCAUCUCCGGCCA
CGCCCGCGUCCACCCCGACCUCGGCGUCAUCUGGGUCGACGCCCACACCGACAUCA
ACACCCCCCUCACCACCACCUCCGGCAACCUCCACGGCCAGCCCGUCUCCUUCCUC
CUCAAGGAGCUCAAGGGCAAGAUCCCCGACGUCCCCGGCUUCUCCUGGGUCACCC
CCUGCAUCUCCGCCAAGGACAUCGUCUACAUCGGCCUCCGCGACGUCGACCCCGG
CGAGCACUACAUCCUCAAGACCCUCGGCAUCAAGUACUUCUCCAUGACCGAGGUC
GACCGCCUCGGCAUCGGCAAGGUCAUGGAGGAGACCCUCUCCUACCUCCUCGGCC
GCAAGAAGCGCCCCAUCCACCUCUCCUUCGACGUCGACGGCCUCGACCCCUCCUUC
ACCCCCGCCACCGGCACCCCCGUCGUCGGCGGCCUCACCUACCGCGAGGGCCUCUA
CAUCACCGAGGAGAUCUACAAGACCGGCCUCCUCUCCGGCCUCGACAUCAUGGAG
GUCAACCCCUCCCUCGGCAAGACCCCCGAGGAGGUCACCCGCACCGUCAACACCGC
CGUCGCCAUCACCCUCGCCUGCUUCGGCCUCGCCCGCGAGGGCAACCACAAGCCCA
UCGACUACCUCAACCCCCCCAAG 
 
Bioluminescent imaging (BLI) 
Mice were shaved prior to imaging to minimize absorption of light by black fur, then imaged, and 
total flux values in photon/s calculated as previously described [102]. 
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Alanine aminotransferase analysis 
Alanine aminotransferase (ALT) level determination was performed from plasma samples with a 
Vet Excel Clinical Chemistry Analyzer (Alfa Wassermann Diagnostic Technologies, West 
Caldwell, NJ) per the manufacturer’s instructions. 
 
Ammonia analysis 
Ammonia determination was performed in duplicate from plasma samples per the 
manufacturer’s instructions (Abcam, Cambridge, MA). Prolonged storage of plasma was 
avoided, and testing was generally performed with all samples simultaneously to avoid any 
batch effect.  
 
Plasma and liver amino acids 
The concentration of amino acids in plasma and liver was determined by high-performance 
liquid chromatography as previously described [113]. 
 
Guanidino Compounds 
The concentration of guanidinoacetic acid (GAA) in the plasma and liver was determined by 
using a normal phase hydrophilic interaction column after analyte derivatization as described 
[114]. 
 
Ammonia challenge and ureagenesis 
Mice were fasted for 3-4 hours prior to the beginning of ammonia challenging as previously 
described [81] using 4 mmol/kg 15N ammonium chloride (15NH4Cl) (Cambridge Isotope 
Laboratories, Tewksbury, MA). Blood collections were performed immediately before and at 10, 
30, and 60 minutes after injection also allowing for ureagenesis determination as described 
[115]. 
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Functional arginase analysis 
Hepatic arginase activity was measured in duplicate from liver tissue lysates as previously 
described [27].  
 
Histology and Immunohistochemistry 
Liver tissues were fixed in 10% (v/v) buffered formalin for 48 hours and then stored in 70% 
ethanol. Fixed tissue was embedded in paraffin blocks using standard procedures from which 4 
µm thick sections were collected on microscope slides. Section deparaffinization, rehydration, 
antigen retrieval, and permeabilization were performed as previously described [113]. Sections 
were blocked with 10% (v/v) normal goat serum in PBS for 30 minutes. Sections were then co-
incubated with primary antibodies for arginase (Santa Cruz Biotechnology, Dallas, TX sc-20150) 
and glutamine synthetase (Abcam ab64613) overnight at 4°C. Sections were then co-incubated 
with fluorescent secondary antibodies donkey anti-goat Alexa Fluor 594 (Invitrogen, Carlsbad, 
CA A11058) and goat anti-mouse Alexa Fluor 488 (Invitrogen A11001) for 1 hour at room 
temperature. Section cell nuclei were counterstained with DAPI and mounted with 
VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA) 
and then visualized. 
Hematoxylin and eosin (H&E) and Masson’s trichrome staining were performed by standard 
methods. 
 
mRNA In Situ Hybridization 
 mRNA in situ hybridization was performed using RNAscope technology on the 
automated Leica BOND RX autostainer platform using the RNAScope® 2.5 LS Reagent Kit-
BROWN from Advanced Cell Diagnostics (Newark, CA). An exclusive target probe with 
proprietary sequences was designed by ACD to target arginase 1 mRNA. Control probes to the 
housekeeping gene Mus musculus peptidylprolyl isomerase B (Ppib), mRNA (cat no 313918, 
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ACD) was used as a positive control or the bacterial gene dihydrodipicolinate reductase (DapB) 
(cat no 312038, ACD) as a negative control was also used as a quality control check for tissues.  
Slides were processed using a Leica staining protocol per the user manual Document Number 
322100-USM (ACD). All images were captured at 20X magnification with the Panoramic 250 
Flash II (3DHISTECH, Budapest, Hungary) digital slide scanner. 
 
Electron Microscopy  
Four groups of liver tissues were collected and fixed in 4% (v/v) paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA) plus 2.5% (v/v) glutaraldehyde (Thermo Fisher Scientific) in 
PBS solution at 4°C for several weeks. Each liver sample was prepared for imaging by standard 
methods. (Details of method are provided in SI Appendix).  
 
RNA Isolation 
Total RNA was isolated from approximately 20 mg of homogenized liver tissue with a Roche 
High Pure RNA Isolation Kit (Roche Applied Sciences, Indianapolis, IN) per manufacturer’s 
instructions.  
 
Residual endogenous murine Arg1 mRNA quantitative RT-PCR 
One µg of total RNA was reverse transcribed to cDNA with a Transcriptor First Strand cDNA 
Synthesis Kit (Roche Applied Sciences) per manufacturer’s instructions. Primers for 
endogenous murine Arg1 mRNA were designed to bind to the exon 7-8 junction: Forward primer 
5’-ACATCACAGAAGAAATTTACAAGACAG / Reverse primer 5’- 
TGCCGTGTTCACAGTACTCTTC / Amplicon length-113 nucleotides. After cDNA synthesis, 
quantitative RT-PCR was performed using SsoAdvancedTM Universal SYBR® Green Supermix 
(Bio-Rad) on MyiQTM2 Two-Color Real-Time PCR Detection System (Bio-Rad). Transcript levels 
were analyzed in triplicate using the CT (threshold cycle) values. Target transcript levels were 
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normalized to endogenous murine β-Actin mRNA and fold enrichment was measured using the 
2-ΔΔCt method. 
 
hARG1 mRNA quantitative RT-PCR 
Total RNA was diluted to 10 ng/µL in water. LNP-encapsulated mRNA quantification was 
performed in triplicate with a TaqmanTM RNA-to-CTTM 1 Step kit (Thermo Fisher Scientific) per 
manufacturer’s instruction. For relative quantification of hARG1 mRNA, sample mRNA 
quantification was calculated relative to Taqman-validated primer-probe pair for the murine 
Gapdh housekeeping gene (Thermo Fisher Scientific, Catalog No. 4331182, Assay ID No. 
Hs02786624_g1) using the 2-ΔΔCt method. ARG1 Forward Primer: 
CAAGGACATCGTCTACATCGG; Reverse Primer: ACCTCGGTCATGGAGAAGTA.  
 
Western blot 
Liver tissue was homogenized and 50 µg of protein was transferred, co-incubated with the 
target primary arginase antibody (Santa Cruz Biotechnology sc-20150) and loading control 
primary antibody β-tubulin (Santa Cruz Biotechnology sc-9104) followed by incubation with 
secondary HRP-conjugated goat anti-rabbit antibody (Santa Cruz Biotechnology sc-2004).  
 
Statistical analysis 
All collected data was analyzed with the GraphPad Prism8 (San Diego, CA) statistical package. 
Results were expressed as mean ± standard error of the mean (SEM) and p values were 
determined using one-way ANOVA with Tukey’s multiple comparison’s test, two-way ANOVA 
with Sidak’s multiple comparison’s test, or unpaired T-test when applicable. Error bars represent 
SEM. P < 0.05 were considered significant. 
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Results 
Lipid nanoparticles successfully deliver mRNA to murine livers 
The liver is the primary location of nitrogen detoxification and urea cycle function. 
Therefore, targeted delivery of the LNPs and proper release of the encapsulated mRNA for 
therapeutic protein translation in the liver is crucial to the potential success of this treatment 
modality for arginase deficiency. To examine the ability for our engineered LNPs to traffic to the 
liver we administered a single intravenous (IV) bolus of 2 mg/kg LNP-encapsulated firefly 
(Photinus pyralis) luciferase mRNA (LNP-luc) to wild type (WT) conditional arginase deficient 
mice (Arg1flox/flox) (n = 5 males). Beginning 2 hrs post-LNP-luc injection, mice were administered 
the luciferase substrate, D-Luciferin, and underwent serial BLI. Imaging revealed proper 
localization of functional luciferase protein to the liver as early as 2 hrs post-LNP-luc injection 
that remained detectable by BLI in some animals up to 36 hrs post-injection (Fig. 2-1A). 72 hrs 
after the initial LNP-luc injection, luciferase protein was undetectable by BLI and an additional IV 
bolus of 2 mg/kg LNP-luc was administered at 73 hrs after the first injection. Repeat serial BLI 
revealed comparable liver trafficking and luciferase protein translation and stability kinetics to 
the initial LNP-luc injection (Fig. 2-1A-B). Though protein translation kinetics and half-life will be 
variable and determined by the specific mRNA encapsulated within the LNPs, BLI demonstrated 
the LNPs ability to reliably and repeatedly deliver mRNA to the liver without overt evidence of 
short-term abnormalities.   
 
Pharmacokinetic characterization of LNP-encapsulated arginase mRNA in murine livers 
A human codon-optimized arginase 1 (hARG1) mRNA was designed, synthesized, and 
encapsulated within our biodegradable liver-targeting LNPs (LNP-hARG1). To characterize the 
kinetics of the hARG1 mRNA release from the LNPs and stability within the liver, we performed 
a pharmacokinetic (PK) study in wild type (WT) Arg1flox/flox mice (n = 3 mice per time point). We 
administered a single IV bolus of 2 mg/kg LNP-hARG1 and collected livers at time points 0, 2, 6, 
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12, and 24 hrs and then daily from day 2 to 7 post-injection. Using quantitative real time-PCR 
(qRT-PCR) primers specific for the human codon optimized ARG1 mRNA encapsulated within 
the LNPs, hARG1 mRNA levels in treated livers were determined relative to murine Gapdh 
housekeeping transcript levels. We observed peak and substantial hARG1 mRNA levels in the 
liver at the earliest time point 2 hrs post-injection compared to 0 hr mice that did not receive 
LNP-hARG1 (0 hr: 0.934 ± 9.934 vs 2 hrs: 1.49 x 105 ± 2.06 x 104 relative transcript levels; p < 
0.001) (Fig. 2-1C). After the observed peak at 2 hrs, hARG1 mRNA levels significantly 
decreased by 33.1% by 6 hrs (p = 0.005) and 84.2% by 12 hrs (p < 0.001) relative to 2 hrs post-
injection mRNA levels. By 24 hrs only 4.4% of the 2 hrs post-injection mRNA levels remained (p 
< 0.001) and maintained levels below 0.25% from day 2 to 7 (p < 0.001 each day). 
 
Long-term animal survival after systemic delivery of LNP-hARG1 
Hepatic loss of murine Arg1 expression leads to hyperargininemia, hyperammonemia, 
and death in Arg1-/- mice [52]. Previous studies have demonstrated that delivery of the murine 
Arg1 cDNA by AAVrh10 can rescue a juvenile-lethal arginase deficient murine model, but 
whose therapeutic efficacy may be limited due to hepatocellular division leading to eventual 
dilution and a substantial loss of the transgene [27]. To demonstrate the long-term efficacy of 
LNP-mediated delivery of codon-optimized hARG1 mRNA to successfully treat arginase 
deficiency, adult Arg1flox/flox mice were administered 2.0 x 1011 genome copies of AAV8-thyroxine 
binding globulin (TBG)-Cre recombinase on day 0 to disrupt hepatic expression of the 
endogenous functional murine Arg1 by excision of exons 7 and 8. Beginning on day 14 after 
AAV8-TBG-Cre administration, mice were administered IV either 2 mg/kg LNP-luc or LNP-
hARG1 (n = 10; 5 male, 5 female per group). One group was administered LNP-mRNA weekly 
and another group every 3 days (q3D). Weight was recorded daily, blood was collected weekly, 
and livers were collected at the end of the study or at time of euthanasia for humane endpoints 
or death. Weekly LNP-hARG1 mice demonstrated significant life extension compared to the 
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weekly LNP-luc control mice (p < 0.001), but none exhibited long-term survival and stable 
weights; all weekly LNP-hARG1 mice died or were euthanized for humane endpoints by day 62 
while all weekly LNP-luc mice perished by day 27 (Fig. 2-2A-B). In contrast, q3D LNP-hARG1 
mice exhibited significant life extension (p < 0.001) with 100% survival and without physiological 
signs of hyperammonemia or weight loss to beyond day 77 compared to q3D LNP-luc mice 
where all perished by day 22 (Fig. 2-2C-D). These data demonstrate that delivery of 2 mg/kg 
LNP-hARG1 each 3 days is a therapeutic dose and frequency of administration that can 
successfully extend and maintain long-term survival and health of arginase deficient mice. No 
period of multi-day loading of LNP-hARG1 by daily injections is necessary (Fig. 2-S1). 
 
Functional metabolic recovery of Arg1-/- mice after systemic delivery of LNP-hARG1 
To evaluate the metabolic function of conditional Arg1-/- mice in response to LNP-mRNA 
treatment, plasma was collected over the course of the study and analyzed for various criteria. 
Due to the transient nature of LNP-mRNA treatment, plasma metabolite levels were expected to 
fluctuate depending on timing of plasma collection within the therapeutic q3D dosing interval. 
Therefore, mice (n = 6 per group) were bled every 7 days regardless of timing within the dosing 
interval to collect time points representing the full spectrum within the dosing interval. In weekly 
LNP-luc mice, plasma ammonia levels were measured on day 0 (183.7 ± 26.9 µM) and 
demonstrated significantly increased concentrations that peaked at death on day 21 (692.9 ± 
23.5 µM; p < 0.001) (Fig. 2-3A). Similarly, significantly increased plasma ammonia 
concentrations at death compared to day 0 levels was also found in weekly LNP-hARG1 mice 
(day 0: 120.0 ± 17.8 vs. day 42: 1409.6 ± 449.5 µM; p = 0.002) (Fig. 2-3A) and in q3D LNP-luc 
mice (day 0: 174.1 ± 32.6 vs. day 21: 1505.6 ± 414.5 µM; p = 0.003) (Fig. 2-3B). However, q3D 
LNP-hARG1 mice showed good control and no statistically significant increases in plasma 
ammonia throughout the study compared to day 0 levels, demonstrating amelioration of 
hyperammonemic episodes induced by hepatic Arg1 disruption (day 0: 112.8 ± 36.7 vs. day 14: 
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146.2 ± 42.2, day 21: 122.2 ± 35.2, day 28: 130.5 ± 33.4, day 42: 146.5 ± 22.7, day 56: 101.3 ± 
31.9, day 70: 123.4 ± 24.5, day 77: 163.1 ± 33.7 µM; p > 0.05) (Fig. 2-3B). q3D LNP-hARG1 
plasma ammonia was measured at days 0, 14, 21, 28, 42, 56, 70 and 77 demonstrating levels 
corresponding to 0, 0, 1, 2, 1, 3, 2, and 1 day(s) post last-dose (post-LD), respectively (Fig 3B). 
Mice (n = 5 males per group) administered q3D LNP-hARG1 on day 72 (1 day post-LD) were 
also able to similarly metabolize an ammonium challenge compared to WT control mice after 60 
minutes demonstrating adequate ability to handle exogenous nitrogen loading (Fig. 2-3C). 
To further confirm recovery of ureagenesis, q3D LNP-hARG1 mice on day 72 (1 day 
post-LD) and WT control mice (n = 8 per group; 4 male, 4 female) were administered 
intraperitoneal 15N ammonium chloride and allowed to metabolize into 15N urea for 60 minutes 
before collected blood was measured by GC-MS for 15N urea enrichment (Fig. 2-3DLeft); q3D 
LNP-hARG1 mice metabolized 81.9 ± 11.3% of total WT control 15N urea enrichment levels 
demonstrating no statistically significant difference between the two groups (p > 0.05) (Fig. 2-
3DRight). 
Plasma and liver (n = 6 per group) were also analyzed for selected amino acids critical to 
the urea cycle and nitrogen metabolism pathways. Plasma amino acids were measured on day 
0, 28, 56, and 77 demonstrating levels corresponding to 0, 2, 3, and 1 day(s) post-LD, 
respectively. Plasma arginine and glutamine, both typically found elevated in mice with arginase 
deficiency, were significantly increased at time of euthanasia in q3D LNP-luc mice compared to 
day 0 (ARGD0: 114.6 ± 1.5 µM, vs. ARGD21: 832.5 ± 102.1 µM; p < 0.001) (GLND0: 731.8 ± 47.2 
µM vs. GLND21: 1277.0 ± 243.0 µM; p = 0.020) (Fig. 2-4A-B). However, in q3D LNP-hARG1 
mice, neither plasma arginine nor glutamine observed any statistically significant increase 
throughout the course of the study compared to day 0 (ARGD0 82.3 ± 8.3 µM vs. ARGD28 127.5 ± 
12.09 µM, ARGD56 165.2 ± 36.47 µM, ARGD77: 151.2 ± 34.4 µM, p > 0.05) (GLND0: 584.5 ± 19.1 
µM vs. GLND28: 643.4 ± 32.5 µM, GLND56: 628.0 ± 90.86 µM, GLND77: 784.2 ± 66.7 µM, p = n.s.) 
(Fig. 2-4A-B). Plasma ornithine and lysine were also examined and while neither q3D LNP-luc 
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nor q3D LNP-hARG1 groups demonstrated statistically significant increases throughout the 
study, plasma lysine in q3D LNP-luc at time of euthanasia was trending toward statistical 
significantly increased levels when compared to day 0 (LYSD0 182.5 ± 21.1 µM vs. LYSD21 356.9 
± 103.6 µM, p = 0.096) (Fig. 2-4C-D). 
Hepatic amino acids (n = 6 per group unless otherwise noted) were measured for q3D 
LNP-luc mice at time of euthanasia and for q3D LNP-hARG1 on day 35 (3 days post-LD) and 
day 77 (1 day post-LD). Hepatic arginine concentrations in q3D LNP-luc mice (34.6 ± 5.7 
nmol/mg protein) were significantly higher compared to q3D LNP-hARG1 mice on both day 35 
(2.6 ± 1.1 nmol/mg protein; p < 0.001, n = 4) and day 77 (3.1 ± 0.2 nmol/mg protein; p < 0.001,) 
and WT control mice (2.5 ± 0.2 nmol/mg protein; p < 0.001) (Fig. 2-4E). Liver glutamine 
concentrations in q3D LNP-luc mice (9.0 ± 1.2 nmol/mg protein) were significantly lower 
compared to q3D LNP-hARG1 mice on day 77 (26.4 ± 1.8 nmol/mg protein; p < 0.001), but not 
significantly different from q3D LNP-hARG1 mice on day 35 (19.92 ± 4.6 nmol/mg protein; p > 
0.05, n = 4) or WT control mice (18.0 ± 3.6 nmol/mg protein; p > 0.05) (Fig. 2-4F); ammonia 
does result in the short-term activation of hepatic glutaminase [116] and may be the cause of 
this intracellular glutamine reduction in LNP-luc mice as plasma ammonia is markedly elevated 
in this group (Fig. 2-3B) Hepatic ornithine concentrations, when compared to WT controls (2.0 ± 
0.2 nmol/mg protein), were significantly elevated in q3D LNP-luc (12.1 ± 2.8 nmol/mg protein; p 
= 0.003) and q3D LNP-hARG1 mice on day 35 (11.0 ± 2.3 nmol/mg protein; p = 0.017, n = 4), 
but not significantly elevated in q3D LNP-hARG1 mice on day 77 (4.1 ± 0.7 nmol/mg protein; p 
> 0.05) (Fig. 2-4G). Hepatic lysine concentrations in q3D LNP-luc mice (36.2 ± 7.6 nmol/mg 
protein) were significantly higher compared to q3D LNP-hARG1 mice on both day 35 (7.7 ± 1.8 
nmol/mg protein; p = 0.002, n = 4) and day 77 (5.9 ± 0.6 nmol/mg protein; p < 0.001,) and WT 
control mice (5.1 ± 0.7 nmol/mg protein; p < 0.001) (Fig. 2-4H). 
Guanidino compounds have been found to accumulate in patients with arginase 
deficiency [14, 16, 117]. Therefore, we quantified the accumulation of guanidinoacetic acid (n = 
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6 per group unless otherwise stated) in plasma of q3D LNP-luc mice at time of euthanasia and 
for q3D LNP-hARG1 on day 35 (3 days post-LD) and day 77 (1 day post-LD). There was no 
statistically significant increase between q3D LNP-hARG1 mice on day 35 (3.9 ± 0.6 nM; n = 4) 
and on day 77 (3.0 ± 0.4 nM) and WT controls (2.3 ± 0.2 nM); however, GAA levels of q3D LNP-
luc mice at time of euthanasia were trending toward significantly increased levels (3.8 ± 0.6 nM; 
p = 0.100) compared to the WT controls (Fig. 2-4I).  
To support the plasma GAA studies, hepatic levels were also quantified for q3D LNP-luc 
mice at time of euthanasia and for q3D LNP-hARG1 on day 35 (3 days post-LD) and 77 (1 day 
post-LD) (n = 4 per group). Liver GAA levels in q3D LNP-luc mice (61.5 ± 12.7 pmol/mg of 
tissue) were significantly elevated compared to q3D LNP-hARG1 mice on day 77 (27.3 ± 6.9 
pmol/mg of tissue; p = 0.047) and WT controls (18.8 ± 4.3 pmol/mg of tissue; p = 0.013); levels 
were trending toward significance compared to q3D LNP-hARG1 mice on day 35 (30.5 ± 5.6 
pmol/mg of tissue; p = 0.077) (Fig. 2-4J). 
To examine for potential liver toxicity induced by long-term administration of LNPs, 
plasma was examined for levels of ALT (n = 6 per group), a marker of liver injury, of q3D LNP-
luc mice at time of euthanasia (49.3 ± 17.5 U/L) and q3D LNP-hARG1 mice on D77 (1 day post-
LD) (33.6 ± 3.8 U/L); differences in levels in both groups were not statistically significant 
compared to WT control levels (27.3 ± 3.7 U/L) (p > 0.05 for both comparisons) (Fig. 2-4K). 
Altogether, these data demonstrate the ability for this treatment modality to completely and 
safely recover the metabolic profile of adult arginase-deficient mice.  
 
LNP-hARG1 levels and localization characteristics within Arg1-/- livers 
After the completion of our in vivo and biochemical studies, LNP-mRNA-treated mice 
were euthanized and their livers collected, sectioned, and analyzed to characterize LNP-hARG1 
levels and distribution. hARG1 mRNA in LNP-mRNA-treated livers was determined relative to 
the murine Gapdh housekeeping transcript levels (n = 6 per group). The q3D LNP-hARG1 mice 
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were euthanized on day 77 (1 day post-LD). Mice were found to have a markedly and 
significantly increased level of hARG1 mRNA compared to LNP-luc and WT control mice (p = 
0.022 for both) (Fig. 2-5A). In contrast, weekly LNP-hARG1 mice showed levels of hARG1 
mRNA in large variation and demonstrated no statistically significant differences compared to 
weekly LNP-luc and WT control mice (Fig. 2-S2A). 
Liver lysates from LNP-mRNA-treated mice (n = 6 per group) were analyzed for 
functional ARG1 protein. The q3D LNP-hARG1 mice on day 77 (1 day post-LD) recovered 53.6 
± 6.3% functional ARG1 activity relative to WT control mice (p < 0.001) (Fig. 2-5B). In contrast, 
while weekly LNP-hARG1 mice at time of euthanasia recovered 10.9 ± 1.5% functional ARG1 
activity relative to WT control mice (p < 0.001), these activity levels were found to be not 
significant different from weekly LNP-luc mice at time of euthanasia with 6.4 ± 0.6% functional 
ARG1 activity (p > 0.05) whose expression was too low to maintain survival (Fig. 2-S2B). To 
further confirm these findings, western blot analysis was performed with q3D LNP-hARG1 liver 
collected on day 77 (1 day post-LD) that revealed the strong presence of a single 35 kDa 
isoform of ARG1 derived from LNP-hARG1 compared to WT mouse liver that demonstrates 
both 35 and 37 kDa endogenous Arg1 isoforms (Fig. 2-5C). Weekly LNP-hARG1 livers collected 
at time of euthanasia demonstrated minimal presence of ARG1 protein (Fig. 2-S2C). 
To confirm that any survival extension was due to LNP-hARG1 treatment and not 
maintenance of endogenous murine Arg1 expression, qRT-PCR primers were designed to span 
the endogenous murine Arg1 exon 7 and 8 mRNA junction excised after AAV8-TBG-Cre 
activation. In weekly LNP-mRNA-treated and q3D LNP-luc-treated livers collected at time of 
euthanasia and q3D LNP-hARG1-treated mice on day 77 (1 day post-LD) there was absence of 
endogenous murine Arg1 mRNA compared to WT control levels (p > 0.05 for both) (Fig. 2-S2D-
E). 
Livers collected from weekly LNP-hARG1 and q3D LNP-luc mice collected at time of 
euthanasia, and q3D LNP-hARG1 mice on day 77 (1 day post-LD) were sectioned and 
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underwent various imaging analyses. hARG1 mRNA presence in LNP-mRNA-treated livers was 
visualized using in situ hybridization (ISH) probes designed specifically for hARG1 mRNA that 
was LNP-encapsulated. ISH of q3D LNP-hARG1 livers on day 77 collected 24 hrs after the final 
LNP-hARG1 dose revealed positive but low presence of hARG1 mRNA in both hepatocytes and 
Kupffer cells (Fig 2-6); hARG1 mRNA levels were in accordance with previous PK data that 
demonstrated significant reduction in hARG1 mRNA after 24 hrs post-LNP-hARG1 injection (Fig 
2-1C). Weekly LNP-hARG1 mice similarly euthanized 24 hrs after the final LNP-hARG1 dose 
also demonstrated positive but lower presence of hARG1 mRNA compared to q3D LNP-hARG1 
livers by ISH (Fig. 2-S3). Immunofluorescent staining for ARG1 and glutamine synthetase (GS), 
to differentiate periportal (GSNegative) and perivenous (GSPositive) vasculature, was performed on 
weekly and q3D LNP-mRNA-treated liver sections to visualize localization of ARG1 expression. 
For weekly LNP-hARG1 livers collected at time of euthanasia, no expression of ARG1 could be 
visualized, further confirming results from the molecular analysis (Fig. 2-S3). However, q3D 
LNP-hARG1 livers on day 77 (1 day post-LD) revealed strong ARG1 expression primarily 
localized in the periportal and interportal spaces consistent with LNP-hARG1 hepatic entrance 
via periportal vasculature and diffusion out to peripheral hepatocytes (Fig. 2-6). All liver sections 
were also stained with H&E revealing no overt pathological hepatic abnormalities or lymphocytic 
infiltrates, and with Masson’s trichrome where absence of dark blue staining indicated lack of 
hepatic fibrosis or collagen deposition (Fig. 2-6). Furthermore, liver sections were imaged by 
electron microscopy to reveal intricate subcellular structures. All groups showed regular 
organization of the hepatic tissue without evidence of accumulation of electron-dense inclusions 
or bundles of collagen fibers. Hepatocytes demonstrated normal nuclear membranes, rough 
endoplasmic reticulum and mitochondrial morphology. Compared to the wild type and LNP-
hARG1-treated mice, LNP-luc hepatocytes did reveal mitochrondria that were slightly enlarged 
(Fig. 2-6 and Fig. 2-S3) and the occasional presence of a lipid droplet (arrow) (Fig. 2-6). 
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Discussion 
Urea cycle disorders are a family of inherited metabolic conditions of the liver in any of 6 
enzymes or 2 transporters which impair ureagenesis and normal nitrogen detoxification 
produced as a consequence of protein metabolism [118]. They are caused by monogenic loss 
of enzyme or transporter function, and are combined with straight-forward medical treatments 
(i.e. protein-restricted diet, ammonia scavengers) that do not address the underlying cause. 
Urea cycle disorders can result in the rapid development of hyperammonemia characterized by 
symptoms and signs including headaches, hypo/hyperventilation, seizures, coma and potentially 
death [5]. Survivors typically have intellectual disabilities and remain vulnerable to repeat 
episodes of hyperammonemia with their cumulative and permanent neurological injury.  
Arginase deficiency (OMIM #207800), caused by biallelic mutations in arginase 1, tends to be 
recognized in late infancy to early childhood, unlike the other urea cycle disorders where 
hyperammonemia and related signs often occur within a few days of birth [5, 12]. Often 
identified by a presentation of spastic paraparesis or quadraparesis, the condition has 
progressive neurological decline including developmental delays, psychomotor and growth 
retardation and seizures as characteristic findings [12]. While the potential for diagnosis by 
newborn screening would enable earlier therapeutic intervention [119], the current treatment is 
less than fully effective at best, resulting in progressive neurological injury. As such, arginase 
deficiency is another example of the growing number of metabolic diseases that can be 
detected by newborn screening but lack fully effective therapies. 
In these present studies, we asked the question whether encapsulation of human codon-
optimized ARG1 mRNA within liver-targeting lipid nanoparticles and their systemic delivery to 
arginase deficient mice can achieve therapeutic recovery of urea cycle function at a reasonable 
concentration, dosage and frequency and result in normal biochemical parameters. We 
demonstrate that administration of 2 mg/kg LNP-hARG1 every 3 days results in both 
biochemical and functional efficacy of hARG1 mRNA. Unlike arginase 1-deficient mice treated 
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with a control mRNA (2 mg/kg LNP-luc q3D) where all mice perished by day 22, we achieved 
100% survival beyond 11 weeks, stable weight, and recovery of urea cycle function with LNP-
hARG1 as demonstrated in part by maintenance of normal plasma ammonia and urea cycle-
related amino acid levels including glutamine. Notably, maintenance of normal plasma ammonia 
and amino acid levels was sustained throughout the q3D dosing interval with analysis occurring 
1, 2 and 3 days post-LD. Importantly, unlike some other metabolic disorders where restored 
hepatic expression results in incomplete correction due to other metabolite-producing 
uncorrected tissues [e.g. methylmalonic acidemia [120]], plasma arginine was completely 
normalized as the urea cycle is exclusive to the liver. In addition, the generation of disease-
related metabolites (i.e. GAA) are prevented and repeat administration of hARG1 mRNA led to 
stable weights, an indication of their overall health. The distribution of the exogenous arginase 
protein was pan-hepatic, as occurs naturally and is in contrast to the other urea cycle enzymes 
which concentrate in the peri-portal areas. 
Pharmacokinetic studies revealed the lipid nanoparticle as an effective delivery vehicle 
of hARG1 mRNA in vivo leading to peak levels of hARG1 mRNA in the liver shortly after 
administration. Significant degradation of LNP-mRNA within 24 hours is consistent with other 
studies [120]. Functionally, whereas control mice demonstrated no hepatic arginase activity and 
perished, translated ARG1 protein from LNP-hARG1 persisted even after significant hARG1 
mRNA degradation leading to 54% of normal hepatic arginase activity 24 hours after 
administration. This led to mice (1 day post-LD) being able to completely metabolize an 
exogenous challenge of ammonia into urea. In addition, ureagenesis was reestablished with 
similar 15N incorporation in mice (1 day post-LD) compared to wild type mice. While analyses 
aimed to quantify hARG1 mRNA and translated protein levels in the liver as well as in vivo 
efficacy of LNP-hARG1 through exogenous ammonia challenges and recovery of ureagenesis 
were performed on mice 1 day post-LD, a time point expected to have high ARG1 expression, 
we nonetheless have demonstrated the sustained efficacy of LNP-hARG1 throughout the q3D 
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dosing interval as evidenced by maintenance of normal weight, plasma amino acids and 
prevention of GAA accumulation in mice 3 days post-LD. 
LNP-hARG1 also led to normalization of intracellular arginine levels in hepatocytes; this 
is not achievable with enzyme replacement therapy (presently in clinical trial [NCT03378531]) 
due to the inability of the PEGylated enzyme to enter hepatocytes [19]. Though further studies 
need to be performed, we hypothesize that normalization of intrahepatic arginine levels (not only 
plasma arginine levels) is needed to avoid the accumulation of disease-related metabolites such 
as GAA. 
With concern for long-term toxicity issues related to repeat dosing of LNPs, we 
demonstrated that at the end of the 11-week study there was no histologic or enzymatic 
evidence of liver injury. Further examination with electron microscopy demonstrated 
hepatocytes with normal nuclear membranes, rough endoplasmic reticulum and mitochondrial 
morphology. Taken together, within the duration and scope of our study, repeat LNP-hARG1 
dosing allowed for long-term survival and maintenance of normal plasma ammonia without 
evidence of hepatocellular injury. 
We did find better survival and normalization of plasma ammonia during the q3D dosing 
period than with weekly administration. As human arginase-deficient patients uncommonly have 
hyperammonemia, the murine model, however, presents with both hyperammonemia and 
hyperargininemia, with the former leading to death. In this model, the q3D dosing is needed for 
extended therapeutic efficacy and survival. Along with q3D dosing, we examined 2 mg/kg LNP-
hARG1 administered weekly and demonstrated significant life extension; however, the weekly-
dosed mice exhibited unstable weights, significant increases of plasma ammonia by the end of 
each week, and eventually they succumbed to hyperammonemia. Notably, some weekly-dosed 
mice had positive presence of hARG1 mRNA by the time of death or euthanasia; however, 
western blot and a functional assay demonstrated minimal hARG1 protein expression, 
potentially due to inadequate time for proper protein translation and the progression of disease 
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in the mice. Thus, while further frequency optimization will be necessary for clinical application, 
human patients may not require the frequency of administration utilized in these murine studies. 
Though progress has been made by way of advancements with both integrating- and non-
integrating viral vector- and non-viral-based technologies to restore enzyme function, these 
gene therapy methods, for arginase deficiency, generally remain in the pre-clinical stage [27, 
28, 80] and exhibit potential disadvantages. These include risk for insertional mutagenesis [101] 
and limited efficacy due to hepatocellular division [102] with viral-based strategies, lack of 
availability of cellular- [69] and organ-based strategies [121], and inability for hepatocyte 
penetrance with PEGylated enzyme replacement [19]. Though highly promising and potentially 
curative, these strategies must be studied further to ensure effectiveness and safety before 
consideration of clinical applicability. Delivering mRNA to the liver is an alternative strategy to 
provide missing or defective enzyme function. With the ability to repeatedly dose lipid 
nanoparticles that carry hARG1 mRNA, supported by the pharmacokinetic studies that 
demonstrate the rapid onset of expression and the tolerability of multiple dosing, suggests the 
value and preclinical proof-of-concept efficacy of lipid nanoparticle-based arginase 1 mRNA 
therapy as an effective therapy for arginase deficiency. 
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Figure 2-1. Lipid nanoparticle-mediated mRNA delivery to the liver results in repeatable 
hepatic expression. Wild type conditional arginase 1 knockout mice were administered an 
intravenous bolus dose of 2 mg/kg of lipid nanoparticle encapsulating mRNA expressing firefly 
luciferase (LNP-luc) (or human codon-optimized ARG1 (LNP-hARG1). (A) Bioluminescent 
imaging of hepatic luciferase expression represented by pseudocolor scale was performed at 
various time points (0, 2, 6, 12, 24, 36, 48, 72 hours) after the first LNP-luc dose with repeat 
imaging after the second bolus administration (2, 6, 12, 24, 36, 48, 72 hours; 4, 5, 6, 7 days; n = 
5 mice per time point). All images were acquired and processed with the same settings. (B) 
Quantitation of hepatic expression of firefly luciferase was performed after the initial LNP-luc 
bolus injection and after repeat administration. (C) The pharmacokinetics of hARG1 mRNA in 
the liver was determined by quantitative real-time PCR after liver collection at various time 
points (0, 2, 6, 12, 24 hours; 2, 3, 4, 5, 6, 7 days; n = 3 per time point). P values obtained from 
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one-way ANOVA with Tukey’s multiple comparison’s test. (*) represents p < 0.001 compared to 
2 hrs post-injection hARG1 mRNA levels. Data is presented as mean ± SEM. 
 
Figure 2-2. Survival and weights of conditional arginase 1 knockout mice were stable 
long-term in mice administered LNP-formulated hARG1 mRNA every 3 days. Conditional 
arginase knockout mice were administered 2 x 1011 genome copies of AAV8-TBG-Cre 
recombinase (day 0) to induce cre-lox excision in the endogenous murine Arg1 gene resulting in 
loss-of-function. Mice were administered an IV bolus of 2 mg/kg LNP-luc (control, black line) or 
2 mg/kg LNP-hARG1 (experimental, red line) (A, B) weekly or (C, D) every 3 days (q3D) 
beginning on day 14. Mice were monitored for survival and clinical evidence of deterioration in 
both the weekly-dosed and q3D-dosed groups up to 11 weeks after initiating cre-lox 
recombination (n = 10 per group, 5 males and 5 females). (B, D) Solid black line (LNP-luc) and 
red line (LNP-hARG1) parallel to X-axis of weight logs represent surviving animals in each 
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treatment study. (A, C) p < 0.001 obtained by log-rank. Data is presented as mean ± SEM. ([B, 
D] Day of LNP injection is represented by darkened red square (n) for LNP-hARG1 and solid 
black circle (•) for LNP-luc.) (g = gram) (TBG = thyroxine binding globulin promoter; Cre = cre 
recombinase)  
 
Figure 2-3. Administration of LNP-hARG1 every 3 days results in controlled plasma 
ammonia and near normal ureagenesis. Conditional arginase knockout mice were 
administered 2 x 1011 genome copies of AAV8 TBC-Cre recombinase (day 0) to induce cre-lox 
excision in the endogenous Arg1. Mice were administered an IV bolus of 2 mg/kg LNP-luc 
(control, black line) or 2 mg/kg LNP-hARG1 (experimental, red line) (A) weekly or (B) every 3 
days (q3D) (n = 6 per group) beginning on day 14. (A) Plasma ammonia was measured in 
weekly-dosed mice on day 0, 14, 21, 28 and 42 in the morning before subsequent injection of 
LNP-mRNA in the afternoon (n = 6 per group). (B) Plasma ammonia was measured in q3D-
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dosed mice on days 0, 14, 21, 28, 42, 56, 70 and 77 demonstrating levels corresponding to 0, 0, 
1, 2, 1, 3, 2, and 1 day(s) post-last-dose (post-LD), respectively (n = 6 per group). (C) q3D LNP-
hARG1-treated mice on day 72 (1 day post-LD) (red line; n = 6) and wild-type (WT) controls 
(Arg1flox/flox; blue line; n = 6) were administered 0.4 M ammonium chloride IP and plasma 
ammonia was measured 10, 30, and 60 minutes post-challenge. (D) Ureagenesis was assessed 
at 10, 30 and 60 minutes after IP administration of 0.4 M 15N ammonium chloride on day 72 (1 
day post-LD) in q3D LNP-hARG1 and WT control mice by 15N urea enrichment quantitation by 
GC-MS (n = 8 per group). Left graph demonstrates progression of 15N urea enrichment at each 
time point. Right graph demonstrates total calculated area under the curve to depict total 
accumulated quantity of 15N urea enrichment of each group. Right graph values are normalized 
to average total area under the curve value of WT control mice. P values obtained from (A-B) 
one-way ANOVA with Tukey’s multiple comparison’s test, (C, DLeft) two-way ANOVA with 
Sidak’s multiple comparison’s test, and (DRight) unpaired T-test. Data is presented as mean ± 
SEM. (TBG = thyroxine binding globulin promoter; Cre = cre recombinase; n.s. = not significant) 
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Figure 2-4.  LNP-hARG1 administration every 3 days prevents elevated plasma and 
hepatic arginine, controls plasma glutamine and prevents guanidinoacetic acid 
accumulation in the plasma. (A) Plasma arginine, (B) glutamine,  (C) ornithine and (D) lysine 
were assessed in every 3 day (q3D) control LNP-luc mice (n = 6; black) at day 0 and 28 and in 
q3D LNP-hARG1 mice (n = 6; red) at day 0, 28, 56, and 77 demonstrating levels corresponding 
to 0, 2, 3, and 1 day(s) post-last-dose (post-LD), respectively. (E) Hepatic arginine, (F) 
glutamine, (G) ornithine and (H) lysine were similarly assessed in control q3D LNP-luc mice at 
time of euthanasia (n = 6; black) and in q3D LNP-hARG1 mice on day 35 (3 days post-LD; n = 
4; green) and on day 77 (1 day post-LD; n = 6; red) and compared with wild type (WT) control 
liver (n = 6; blue). (I) Plasma guanidino compounds, represented by guanidinoacetic acid, was 
assessed in q3D LNP-hARG1 mice on day 35 (3 days post-LD; n = 4; green) and on day 77 (1 
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day post-LD; n = 6; red) and compared with q3D LNP-luc (n = 6; black) and WT controls (n = 6; 
blue). (J) Liver guanidinoacetic acid was assessed similarly to (I) (n = 4 per group). (K) Plasma 
ALT was assessed in q3D LNP-hARG1 on day 77 (1 day post-LD; n = 6; red) and compared 
with q3D LNP-luc at time of euthanasia (n = 6; black) and WT controls (n = 6; blue). P values 
obtained from one-way ANOVA with Tukey’s multiple comparison’s test. Data is presented as 
mean ± SEM. (n.s. = not significant) 
 
Figure 2-5. LNP-hARG1 administration results in restoration of hepatic arginase mRNA 
and protein. (A) hARG1 mRNA hepatic levels relative to murine Gapdh housekeeping gene 
was assessed by quantitative real-time PCR and (B) functional hepatic ARG1 activity was 
assessed by a biochemical functional arginase assay in every 3 day (q3D) LNP-hARG1 mice on 
day 77 (1 day post-last-dose) and compared with q3D LNP-luc at time of euthanasia and wild 
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type (WT) controls (n = 6 per group). (C) Western blot analysis of hepatic ARG1 transgene 
expression in q3D LNP-hARG1 mice on day 77 (1 day post-last-dose) was compared with q3D 
LNP-luc at time of euthanasia and WT control liver. P values obtained from one-way ANOVA 
with Tukey’s multiple comparison’s test. Data is presented as mean ± SEM. 
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Figure 2-6. LNP-hARG1-mediated protein is detected in the liver when administered by 
lipid nanoparticle without evidence of inflammatory infiltrates, fibrosis, or subcellular 
injury.  Liver sections of representative images of every 3 day (q3D) LNP-luc mice at time of 
euthanasia, q3D LNP-hARG1 mice on day 77 (1 day post-last-dose), and wild type (WT) control 
mice were examined for: hARG1 mRNA presence by in situ hybridization (RNAscope®) (top 
row-20X magnification); ARG1 transgene expression with greater perivenous vascular 
localization by immunostaining for ARG1 (red) and glutamine synthase (green) (2nd row-20X 
magnification); hepatic histology by hematoxylin and eosin (H&E) staining (3rd row-40X 
magnification); examination for collagen deposition/fibrosis by Masson’s trichrome staining (4th 
row-20X magnification); and electron microscopy (5th row-8-10,000X magnification, 6th row-
60,000X magnification). (arrows denote lipid droplets) 
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Fig. 2-S1. Conditional arginase knockout mice were administered 2 x 1011 genome copies of 
AAV8-TBG-Cre (day 0) to induce cre-lox excision in endogenous murine Arg1 resulting in loss-
of-function. (A) Mice were administered a multi-day loading of 2 mg/kg LNP-luc (control, black 
line) or 2 mg/kg LNP-hARG1 (experimental, red line) every day beginning on day 14 to 21 and 
then dose frequency reduced to every 3 days (D14-21 qD Load + q3D). (A, B) Mice were 
monitored for survival and clinical evidence of deterioration up to 11 weeks after initiating cre-lox 
recombination (n = 5 females). (B) Solid black line (LNP-luc) and red line (LNP-hARG1) beneath 
weight log illustrates number of mice remaining in treatment study. (C) Plasma ammonia was 
measured on days 0, 14, 21, 28, and 63 corresponding to 0, 0, 1, 1, and 3 days post-last-dose 
(post-LD) (n = 2 females). (D) Ureagenesis was assessed at 10, 30 and 60 minutes after IP 
administration of 0.4 M 15N ammonium chloride on day 72 (1 day post-LD) in D14-21 qD Load + 
q3D and wild type (WT) control mice by 15N urea enrichment quantitation. Left graph 
demonstrates progression of 15N urea enrichment at each time point. Right graph demonstrates 
total calculated area under the curve to depict total accumulated quantity of 15N urea enrichment 
of each group. Right graph values are normalized to average total area under the curve value of 
WT control mice (n = 5 females per group). (E) Hepatic arginase activity was assessed by a 
biochemical functional arginase assay in D14-21 qD Load + q3D LNP-luc at time of euthanasia, 
D14-21 qD Load + q3D LNP-hARG1 on day 72 (1 day post-LD), and WT control livers (n = 3 
females) (F) Liver sections of representative images of D14-21 qD Load + q3D LNP-luc at time 
of euthanasia, D14-21 qD Load + q3D LNP-hARG1 on day 72 (1 day post-LD), and WT control 
livers were examined for ARG1 transgene expression by immunostaining for ARG1. P values 
obtained by (A) log-rank, (C, E) one-way ANOVA with Tukey’s multiple comparison’s test, (DLeft) 
two-way ANOVA with Sidak’s multiple comparison’s test, and (DRight) unpaired T-test. Data is 
presented as mean ± SEM. ([B] Day of LNP injection is represented by darkened red square (n) 
for LNP-hARG1 and solid black circle (•) for LNP-luc.) (g = gram) (TBG = thyroxine binding 
globulin promoter; Cre = cre recombinase) 
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Fig. 2-S2. (A) hARG1 mRNA hepatic levels relative to murine Gapdh housekeeping gene was 
assessed by quantitative real-time PCR and (B) hepatic arginase activity was assessed by a 
biochemical functional assay in weekly LNP-hARG1 mice and compared with weekly LNP-luc 
and wild type (WT) controls (n = 6 per group). (C) Western blot analysis of hepatic ARG1 
transgene expression in weekly LNP-hARG1 mice that were euthanized for humane endpoints 
at 1, 3, and 5 days or found dead 7 days after the last LNP-hARG1 dose and compared with 
weekly LNP-luc and WT control liver. Residual endogenous Arg1 mRNA levels relative to 
murine Gapdh housekeeping gene was assessed by quantitative real-time PCR in (D) weekly 
LNP-hARG1, weekly LNP-luc, and WT control mice (n = 6 per group) and in (E) every 3 day 
(q3D) LNP-hARG1 on day 77 (1 day post-last-dose), q3D LNP-luc, and WT control mice (n = 6 
per group). P values obtained from one-way ANOVA with Tukey’s multiple comparison’s test. 
Data is presented as mean ± SEM. 
	78 
 
Fig. 2-S3. Liver sections of representative images of weekly LNP-hARG1, weekly LNP-luc, and 
wild type (WT) control mice were examined for: hARG1 mRNA presence by in situ hybridization 
(RNAscope®) (top row-20X magnification); hARG1 transgene expression with perivenous 
vascular localization by immunostaining for ARG1 and glutamine synthase (2nd row-20X 
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magnification); hepatic histology by hematoxylin and eosin (H&E) staining (3rd row-40X 
magnification); collagen deposition/fibrosis examination by Masson’s trichrome staining (4th row-
20X magnification); and electron microscopy (5th row-8-10,000X magnification, 6th row-60,000X 
magnification). 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
  
The urea cycle is an essential pathway for ammonia detoxification and for the regulation 
and disposal of excess nitrogen in mammals. Its disregulation by way of inherited UCDs, though 
uncommon, have significant consequences as afflicted infants and newborns are at substantial 
risk for brain injury and death with standard of care being more prophylactic than curative. 
Arginase deficiency presents in late infancy with chronic therapy often being ineffective at 
preventing the progressive and relentless nature of intellectual decline. Liver transplantation is 
the only known cure, but is an extreme alternative with limited availability.  Though our group 
has demonstrated preclinical data supporting an AAV-based strategy for treatment of arginase 
deficiency, its clinical application is hampered by concerns for eventual transgene dilution as 
pediatric patient livers grow. Therefore, the work presented here aimed to develop a proof-of-
concept of a personalized cellular-based approach that could grow with the patient. However, 
recognizing the preclinical nature and lengthy preparation time of the approach, we investigated 
LNP-encapsulated mRNA that can treat the patient while the more curative cellular approach is 
prepared. 
 
Restoring Ureagenesis in Hepatocytes by CRISPR/Cas9-mediated Genomic Addition to 
Arginase-Deficient Induced Pluripotent Stem Cells 
 The purpose of this study was to determine if hiPSCs could be derived from three 
genetically distinct arginase deficient patients and whether integration of a human codon-
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optimized arginase mediated by a CRISPR/Cas9 nickase system could produce in vitro 
functional arginase after differentiation into hepatocyte-like derivatives for potential use in 
autologous cellular therapy. After obtaining skin punch biopsies from two arginase deficient 
patients and a fibroblast sample from third, we demonstrated that hiPSCs could be successfully 
derived from the diseased lines. We developed a genomic modification system using 
CRISPR/Cas9 nickases to facilitate significant restoration of arginase enzyme function 
integrating into the HPRT safe harbor locus with minimal observed off-target effects. We then 
established a protocol to differentiate our gene-added hiPSCs into HLCs that demonstrated 
significant arginase enzyme function.  
 However, after differentiation to HLCs, a significant reduction of arginase RNA and 
functional activity was observed, but nonetheless, >40% of functional arginase activity was 
maintained relative to the human fetal liver controls; this decrease also raised concerns of 
continued transgene reduction upon post-transplantation in vivo. We hypothesized that this 
transgene reduction was due to the use of the hEF1α promoter as it has been shown to 
undergo silencing post-differentiation. Efforts were performed to determine if pairing the hEF1α 
promoter with a UCOE could better maintain post-differentiation transgene expression, but 
similar levels of silencing were observed. Therefore, future arginase expression cassettes 
should use promoters expressed highly in the liver such as the albumin promoter. Additionally, 
instead of targeting the HPRT locus, the arginase transgene could target the endogenous 
albumin locus by integration either directly behind the endogenous promoter or linked to the 3’ 
end of the albumin gene by a self-cleaving 2A peptide.  
 Additionally, further efforts were performed to derive more mature HLCs where different 
differentiation protocols and an AFP-Reporter/Selection Construct (ARC) were examined. An 
updated differentiation protocol based on the Carpentier et. al. protocol established a more 
mature HLC phenotype, though low expression of urea cycle enzymes still indicated fetal-like 
characteristics. Therefore, additional protocols should be further investigated utilizing 2D-based 
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strategies and also 3D-based liver bud protocols [39, 122]. An ARC was also examined to be 
able to select for AFP-positive expressing cells to remove non-hepatic derivatives from a 
heterogeneous population of HLCs. Though selection by antibiotic resistance slightly enriched 
for an AFP-positive population, it caused significant loss of hepatic morphology and gene 
expression. However, selection by FACS did modestly improve the hepatic gene expression, 
but clinical application would be limited due FACS machine constraints such as throughput and 
application of adverse cellular mechanical stress. Therefore, future reporter constructs should 
likely be based on albumin expression and also use an alternative and gentler antibiotic such as 
neomycin or puromycin.   
   To determine if our gene-added HLCs could contribute to in vivo urea cycle function, 
we developed an immunosuppressed arginase deficient mouse model. However, at present, we 
have not been able to successfully engraft and repopulate the murine livers with our hiPSC-
derived HLCs though we have demonstrated successful engraftment and repopulation of murine 
livers with intrasplenic injection of 1x106 primary human hepatocytes. Future engraftment and 
repopulation studies will try to determine if lack of engraftment potential is due to hiPSC-derived 
HLC lack of maturity or potentially a need to transplant more cells per animal.   
 
Lipid Nanoparticle Targeted mRNA Therapy as a Treatment for the Inherited Metabolic Liver 
Disorder Arginase Deficiency 
 Though there is promising progression being made in the field to develop a patient-
specific pluripotent stem cell-based gene therapy approach for treatment of UCDs such as 
arginase deficiency and other monogenic liver disorders, these therapies remain in the 
preclinical stage. Even if established, deriving patient-specific genomically modified HLCs is 
time consuming. Consequently, during the several months of cellular therapy preparation, 
patients can remain vulnerable to the progressive intellectual deterioration as conventional 
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standard of care can prove to be ineffective. Therefore, we were determined to investigate a 
readily available treatment strategy to bridge the gap. 
 Delivery of mRNA encapsulated in LNPs for in vivo systemic delivery for uptake by 
hepatocytes is an alternative strategy to provide missing or defective enzyme function. In this 
study, we systemically administered LNPs targeting the liver that were encapsulating human 
codon optimized ARG1 mRNA and were able to achieve functional expression of the enzyme in 
a conditional knockout model of arginase deficiency. Metabolically, this resulted in maintaining 
normal plasma ammonia and arginine, preventing the buildup of excessive hepatic arginine, and 
obviated the development of guanidino compounds, a hallmark of this enzyme deficiency. 
Unlike controls, repeat dosing of LNPs led to long-term survival without evidence of toxicity, 
restoration of ureagenesis and the ability to handle toxic ammonia loading.  
 Though we did not detect any hepatotoxicity, adverse immune responses, or 
accumulation of lipids in the liver through the duration of our experiment, the dosing frequency 
and concentration of 2 mg/kg q3D is relatively high compared to other studies treating as low as 
0.5 mg/kg weekly [112]. However, since our conditional knockout model does not perfectly 
recapitulate the human pathobiology, optimization of dosage and frequency of LNP-hARG1 in a 
clinical human disease context will be required. Alternatively, further modifications to the 
chemically modified mRNA to optimize mRNA stability and translation efficiency or to the LNP 
formulation to enhance hepatocyte uptake and endosomal escape may also help reduce the 
dosage and frequency.  
 As these studies evaluating LNP-hARG1 were performed in an adult conditional 
knockout model of arginase deficiency, additional studies should be performed in the 
constitutive knockout model [27]. Though we demonstrated by qRT-PCR the absence of any 
residual endogenous arginase after administration of AAV8-TBG-Cre recombinase, the 
constitutive knockout model will allow us to determine if treatment with LNP-hARG1 can lead to 
long-term survival in this juvenile lethal arginase deficient mouse model [27]. Additionally, as the 
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conditional knockout model’s immune system has been exposed and tolerized to the wild-type 
endogenous arginase protein, the constitutive knockout may serve as an appropriate model to 
examine any potential immune response to the foreign human protein. Additionally, dosage and 
frequency of administration will need to be optimized as hepatocellular division is rapid in 
newborn mice and enzymatic requirements may increase as the mice grow. Furthermore, route 
of LNP-hARG1 administration will need to be carefully considered and optimized as IV injections 
in newborn mice may not be feasible until ~P13, approximately the period when this mouse 
model perishes or requires euthanasia. However, alternative routes of injections may cause 
significant shifts in pharmacokinetics and biodistribution of the LNP-hARG1 and thereby alter 
dosage and frequency requirements. These findings and future studies have implications for 
therapy of arginase deficiency, which is presently inadequately treated and leads to progressive 
neurological decline.  
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